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1. Introduction & objectives 
1.1 Introduction 
 
Probiotic bacteria are well known for their supportive effects in human health, mainly 
boosting immune homeostasis by altering microbial balance and interacting with the 
immune system (Calder & Kew, 2002; Cummings, et al., 2004; Galdeano, et al., 2007). In 
spite of considerable body of information concerning the protective effects of probiotics, 
little is known about their basic molecular mechanisms by which they exert beneficial 
effects in viable or non-viable state.  In fact, understanding the mechanism by which 
different forms of probiotics govern the type of immune response could be of crucial 
importance for development of novel approaches to immune therapy and generation of 
functional foods. 
 One of the general understandings is that dendritic cells (DCs) as the professional antigen 
presenting cells play a pivotal role in initiation and regulation of immune response by 
processing the microbial products and presenting them together with Major 
histocompatibility complex (MHC) proteins and co-stimulatory molecules to lymphocytes 
(Drakes, et al., 2004; Q. Huang, et al., 2001; X. L. Huang, et al., 2008; H. K. Lee & 
Iwasaki, 2007; Steinman, 2001). Therefore, the observed immunomodulatory effects of 
probiotic bacteria could result from the interaction between probiotic bacteria and DCs 
where they can provide maturation stimulus, along with secretion of cytokines and 
chemokines and ultimately determine the direction of immune response toward T helper 
cell type 1 (TH1), T helper cell type 2 (TH2) or tolerance by targeting DCs (Christensen, et 
al., 2002) 
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It is already known that different strains of probiotics can provoke very distinct DC 
maturation patterns and each strain seems to utilize different mechanisms to generate the 
immune response in a dose dependent manner.  However, probiotics interaction with DCs 
is believed to lead to an immunoregulatory state rather than aggressive immune response 
(Foligne, et al., 2005; Smirnov, et al., 2002; Smits, et al., 2005; Smits, et al., 2001).  
So far, most studies have focused on the effect and mechanism of action of viable strains 
or their cell wall components, but there is an increasing interest in the application of 
probiotics as microbiologically non-viable yet immunologically active products in the food 
industry and novel supplement production. Producing and transporting the biological 
products based on dead cells are definitely simpler. Indeed, they would be relatively easy 
to standardize and would have a long shelf life (Adams 2010).  
 So our primary focus in the present study was to investigate the adjuvanticity of the heat-
inactivated form of two well documented and widely consumed probiotics i.e., 
Lactobacillus rhamnosus GG (LGG) and lactobacillus delbrueckii subsp. bulgaricus 
(L.delbrueckii) on immature human monocyte derived dendritic cells (MODCs). Pattern of 
expression of co-stimulatory molecules, in particular those from B7 family, as phenotypic 
DC maturation markers, as well as extracellular cytokine production were analyzed to 
assess the immune response of LGG and L.delbrueckii on DCs. 
Moreover, it is well known that the immune response is initiated by discrimination of 
pathogens from commensal bacteria and probiotics via certain toll like receptors (TLR) 
(An, et al., 2002).Based on this initial recognition a network of complex of interacting 
downstream signaling cascades become activated which ultimately determine the fate of 
immune response.  So the second focus of our study was to investigate if non-viable LGG 
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and L.delbrueckii influence expression of TLR4. Moreover, we investigated if the 
expression of, inhibitor of nuclear transcription factor NFκB (IκB), and P38 mitogen 
activated protein kinase (MAPK) as representative of signaling regulators in complex 
network of inflammatory signaling path ways are modified in probiotics- treated dendritic 
cells. 
On the other hand an entirely new paradigm of immune regulation has been proposed after 
discovery of single-stranded small non-coding RNAs i.e.,  microRNAs (miRNAs)  and 
identification of their role in immune homeostasis (Bartel, 2004). The regulation of 
miRNA expression is known to be tightly controlled and altered levels or temporal 
expression of a specific miRNA clearly affects the function of immune cells. So it was our 
third particular interest to look if certain miRNAs that participate in the fine regulation of 
immune response at post transcriptional level are affected by probiotics, which can provide 
epigenetic explanation for probiotics mechanism(Kuipers, et al., 2010). In this context we 
analyzed expression of two validated miRNAs for DCs i.e., miR-155 and miR-146a after 
12 hours co-incubation with heat-inactivated LGG and L.delbrueckii.   
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1-2 Objectives  
  1-2-1 General objective  
To determine if heat inactivated Lactobacillus Rhamnosus GG (LGG) and Lactobacillus 
delbreuckii (L.delbrueckii) are able to induce immune regulatory effect as their viable 
forms, through the putative mechanisms of action including regulation of phenotypic 
changes, cytokine production, expression of signaling factors and expression of miRNA in 
dendritic cells.  
  1-2-2 Specific objectives  
• To determine the expression of co-stimulatory molecules involved in DC 
maturation and activation (CD 11c, CD 14, CD 54, CD 80, CD 83, CD 86, CD 209, 
HLADR) after being 24 hours treated with LGG and L.delbrueckii. 
• To determine inflammatory cytokine (IL1-β, INF-γ, IL-12, Tumor necrosis factor 
(TNF-α) and anti-inflammatory cytokine (IL-10) levels produced from DCs after 
being 24 hours treated with LGG and L.delbrueckii. 
• To determine the expression of major signaling elements (TLR4, IKB,P38) in DCs 
after 12 hours co-incubation with LGG and L.delbrueckii. 
• To determine the expression of miR146a and miR155 in DCs after 12 h ours co-
incubation with LGG and L.delbrueckii. 
• To compare  the effect of inactivated  LGG and L.delbrueckii in induction of  CD 
11c, CD 14, CD 54, CD 80, CD 83, CD 86, CD 209, HLADR expression  
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• To compare  t he effect of inactivated  LGG and L.delbrueckii in production of 
inflammatory cytokine (IL1-β, INF-γ, IL-12, TNF-α) and anti-inflammatory 
cytokine (IL-10) 
• To compare the effect of LGG, L.delbrueckii and lipopolysacharide (LPS) in 
inducing expression of TLR4, p38 and IKB. 
• To compare the effect of LGG, L.delbrueckii and LPS in inducing expression of 
miR7i, miR146a and miR155. 
  1-2-3 Applied objective  
• To modify the general accepted definition for probiotics by omitting the necessity 
of probiotics to be viable for inducing functional effects. 
• To provide evidence  f or administration of heat-killed probiotics which allows 
longer product shelf life, easier storage, transportation and more convenient and 
safer consumption in form of dietary supplements and food products  
1-3 Hypothesis 
Heat inactivated Probiotic bacteria can induce immune-regulatory effect through 
maturation of dendritic cells, regulating expression of signaling factors and expression of 
the responsible non-coding RNAs in immune cells as the viable probiotics.   
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2. Literature Overview 
2.1 Probiotics 
2.1.1 Discovery and definitions 
 
The word probiotic (pro-“bios”,ie. Pro life) was first proposed for “organisms and 
substances which contribute to intestinal microbial balance (Parker, 1974). However, it 
was Metchnikoff’s theory which gave birth to the concept of probiotics almost a century 
ago. This Nobelist suggested that the long healthy life of Bulgarian peasants resulted from 
consumption of fermented milk products. In his famous book "The prolongation of life” he 
stated that "The dependence of the intestinal microbes on food makes it possible to adopt 
measures to modify the flora in our bodies and to replace the harmful microbes by useful 
microbes" (Caramia, 2008). 
Over years many definitions have been proposed for probiotics and ultimately an expert 
panel commissioned by the Food and Agriculture Organization of the United Nations and 
the World Health Organization in 2001 characterized probiotics broadly as "live 
nonpathogenic microorganisms which, when administered in adequate amounts, confer 
a health benefit on the host". Of course, this definition has not received the universal 
acceptance, due to open delicate points of discussion related to the site of activity, the 
viability of the probiotics strain, the concentration of cells necessary to exert the specified 
probiotics effect, the use of mono– or mixed cultures, the format of intake and its carrier, 
and finally its functionality beyond the inherent basic nutrition(Reid, et al., 2003).  
Probiotic bacteria consist mainly of strains of Lactobacillus, Bifidobacterium, and 
Streptococcu(Klein et al., 1998).  Lactobacilli are often part of the human intestinal 
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ecosystem, but highly variable amounts are found. Probiotics have no necessary 
phylogenic relation to one another and are therefore best defined functionally rather than 
structurally.  
Expected characteristics of potential probiotics strains are listed in table 2.1.1 
Table 2.1.1 characteristics of potential probiotics strains 
 
Characteristics of Potential Probiotics Strains 
Non toxic and non pathogenic 
Accurate taxonomic identification 
Normal inhabitant of the targeted species 
Capable of survival, proliferation and metabolic activity in the target site, which implies: 
Resist to gastric acid and bile 
Able to persist, albeit for short periods, in the gastrointestinal tract, adherence potential 
preferred 
Able to compete with the resident flora 
Able to produce antimicrobial substances 
Antagonism (in vivo) towards pathogenic bacteria 
Able to modulate immune responses 
Able to exert at least one clinically documented health benefit 
Genetically stable 
Amenability of the strain and stability of the desired characteristics during processing, 
storage and delivery 
Viability at high populations 
Desirable organoleptic and technological properties when included in fermentation 
processes 
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2.1.2 General Effects and Functions of Probiotics 
 
The remarkable phenotypic and genotypic variability among isolates belonging to a well–
established species make it imp ossible, at present, to generalize probiotics efficacy. 
Although it is tempting to speculate that one species will mediate several specific effects, 
and that different strains of a particular species have comparable effects, research results 
do not support this conclusion.  Indeed it is unlikely that single strains of lactobacilli, 
Bifidobacterium and other will bear the multitude of proposed benefits. As head-to-head 
comparison on strain-, species- or genus level are very rarely done, generalizations about 
probiotics performance on the genus and species level are impossible to make (Scarpellini, 
et al., 2008).  
The evidence in support of the efficacy of probiotic bacteria varies from circumstantial to 
convincing (Level 1) using evidence-based medicine techniques. Level I evidence now 
exists for the therapeutic use of probiotics in infectious diarrhea in children, recurrent 
Clostridium difficile induced infections, and postoperative pouchitis (Hilton, et al., 1997; 
Kuisma, et al., 2003; Marteau, et al., 2001). Level II evidence is emerging for the use of 
probiotics in other gastrointestinal infections, irritable bowel syndrome, and ulcerative 
colitis(Collado, et al., 2009).  
The best effect of probiotics is known to be achieved when the microorganisms colonize 
the intestinal surface mucus layer, however they can then affect the intestinal immune 
system, displace enteric pathogens, and provide antioxidants, anti-mutagens, and possibly 
other effects by cell signaling. While most probiotics exert their effects when introduced 
9 
 
into the gastrointestinal tract, some exert their effects through systemically administered 
components (Borchers, et al., 2009; Castillo, et al., 2011).  
Broad reading of the probiotics literature reveals that different effects of probiotics have 
been associated mostly to their unique capacities to express particular surface molecules 
(glycolipids, microbe-associated molecular patterns) or to secrete products that have the 
ability to interact with the various components of the epithelial cells forming the epithelial 
barrier or cells in the immune system that lie under this barrier. Some of these properties 
are observable only with viable probiotics while the others are also observable with dead 
probiotics or components derived from dead organisms (Corthesy, et al., 2007; Elmadfa, et 
al., 2010; Liong, 2007; Matsuzaki, et al., 2007; Prisciandaro, et al., 2009).  
Beneficial health effects of probiotics and the proposed mechanisms are summerized in 
table 2.1.2  
Table2. 1  Beneficia Health l effects attributed to lactic acid bacteria   
 
Health benefit proposed mechanism(s) 
Alleviation of lactose intolerance Bacterial β-galactosidase acts on lactose 
Positive influence on intestinal 
flora 
Lactobacilli influence activity of over growth flora, 
decreasing toxic metabolite production 
Antibacterial characteristics 
Prevention of intestinal tract 
infections 
Adjuvant effect increasing antibody production 
Stimulation of the systemic or secretory immune response 
Competitive exclusion 
Alteration of intestinal conditions to be less favorable for 
pathogenicity (pH, short chain fatty acids, bacteriocins) 
Alteration of toxin binding sites 
Gut flora alteration 
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Adherence to intestinal mucosa, preventing pathogen 
adherence 
Competition for nutrients 
Reduction of inflammatory or 
allergic reactions 
Restoration of the homeostasis of the immune system 
Regulation of cytokine synthesis 
Prevention of antigen translocation into blood stream 
Anti-colon cancer effect Mutagen binding 
Carcinogen deactivation 
Alteration of activity of colonic microbes 
Immune response 
Influence on secondary bile salt concentration 
Blood lipids, heart disease Assimilation of cholesterol 
Alteration of activity of bile salt hydrolase enzyme 
Antioxidative effect 
Antihypertensive effect Peptidase action on milk results in antihypertensive 
tripeptides (angiotensin converting enzyme inhibitors) 
Cell wall components act as angiotensin converting 
enzyme inhibitors 
Urogenital infections Adhesion to urinary and vaginal tract cells 
Competitive exclusion 
Inhibitor production (H2O2, biosurfactants) 
Infection caused by Helicobacter 
pylori 
Competitive exclusion 
Lactic acid production 
Decreased urease activity of H. pylori in humans after 
administration of a supernatant of a Lactobacillus culture 
Regulation of gut  motility 
(constipation) 
 
Feeling of well-being  
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2. 1.3 Lactobacillus GG: Unique Native Bacterium in Human GI Tract 
 
Lactobacillus rhamnosus GG (LGG) is a facultatively heterofermentative lactic acid 
bacterium and is frequently isolated from human gastrointestinal mucosa of healthy 
individuals (Verdenelli, et al., 2009). This strain was found in 1983 while Professor 
Sherwood Gorbach and Barry Goldin were searching for a strain of lactobacillus that could 
colonize the human intestine and thereby exert the beneficial effects which Metchnikoff 
had hoped to produce by his yogurt cultures. Finally Lactobacillus rhamnosus GG filled 
for patent on 17th April 1985, by Sherwood Gorbach and Barry Goldin, the 'GG' derives 
from the first letters of their surnames (Silva, et al., 1987). The patent refers to a strain of 
"L. acidophilus GG" with American Type Culture Collection (ATCC) Accession No. 
53103; later reclassified as a strain of L. rhamnosus. The patent claims that the LGG strain 
is acid and bile stable, has a great avidity for human intestinal mucosa cells and produces 
lactic acid.   
 Lactobacillus rhamnosus was originally considered to be a subspecies of L. casei, but later 
genetic research found it to be a species of its own(Avlami, et al., 2001). Indeed, the full 
genome sequence of this strain was reported in 2009 (Morita, et al., 2009). LGG is more 
likely a transient inhabitant, not autochthonous (Walter, 2008).   
Today, LGG is the best-studied and most extensively documented probiotic lactic-acid 
bacteria strain in the world. L. rhamnosus is used as a natural preservative in yogurt and 
other dairy products to extend the shelf life. LGG’s most well known effects  i n human 
revolve around its ability to influence digestive tract health by stabilizing human intestinal 
microflora and hastening the removal of pathogenic microorganisms (Lam, et al., 2007). 
Lactobacillus rhamnosus GG has been studied extensively for its immune-enhancing 
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properties. LGG can influence immune responses both specifically by stimulating antibody 
production and nonspecifically by enhancing phagocytosis(Forestier, et al., 2001; Guarino, 
et al., 2008). It also modifies production of cytokines (Cross, et al., 2002; Pessi, et al., 
2000). New results are indicating that LGG can affect the immune system in a variety of 
populations. Moreover, it can affect the health of organs far apart from the intestinal tract 
(Pena & Versalovic, 2003; Schultz, et al., 2003). 
 The effect of   on e month treatment with LGG was elegantly shown by microarray 
analysis. Up-regulation of 334 g enes and down-regulation of 92 genes involved in 
inflammation, apoptosis, cell-cell signaling, cell adhesion and differentiation and signal 
transcription and transduction clearly show the influences of lactic acid bacteria (LAB) on 
multiple systems (Di Caro, et al., 2005).  
While frequently considered a beneficial organism, L. rhamnosus has been discovered to 
be pathogenic in certain circumstances (Avlami, et al., 2001). 
2.1.4 Lactobacillus Delbrueckii: 
 
Lactobacillus delbrueckii are gram positive, facultative anaerobic, non motile and non 
spore forming, rod shaped members of the industrially important lactic acid bacteria. The 
bacterium has complex nutritional requirements, including the inability to ferment any 
sugar except lactose. The L. delbrueckii species contains three subspecies: L. delbrueckii 
subsp. delbrueckii, L.delbrueckii subsp lactis , and L.delbrueckii subsps, bulgaricus.  
L.delbrueckii subsps. Bulgaricus was first identified on 1905 b y Bulgarian doctor Stamen 
Grigorov, is named after Bulgaria, and is utilized as a component of thermophilic starter 
cultures alongside Streptococcus thermophilus in manufacturing a number of fermented 
dairy products (Hassan, et al., 2001).  Now L.bulgaricus is one of the economically most 
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important representatives of the heterogeneous group of lactic acid bacteria with values of 
more than $2.1 bi llion only in United States due to its application in producing special 
yogurt aroma by fermenting milk and producing acetaldehydes.  
The complete genome sequence of Lactobacillus bulgaricus is also reported (van de 
Guchte, et al., 2006). 
A well documented health benefit of consumption of yogurt containing live L. bulgaricus 
and Streptococcus thermophilus is shown in attenuation of lactose intolerance (Mercenier, 
et al., 2003; Reid, et al., 2003). In addition, immune modulation and diarrhea-alleviating 
effects have been reported (Adolfsson, et al., 2004), and both L. bulgaricus and S. 
thermophilus have been implicated in these effects (Galdeano & Perdigon, 2004; Guarner, 
et al., 2005).  A positive effect of L.bulgaricus  is reported in prevention of autoimmune 
conditions (Kano, et al., 2002).  
2.2. Dendritic Cells: Gatekeepers and orchestrators of immune response 
 
The term “dendritic cells” was first proposed by Steinman in 1973 for a novel cell type 
which has been identified in adherent cell populations prepared from mouse peripheral 
lymphoid organs (spleen, lymph node, Peyer's patch). Though present in small numbers 
(0.1-1.6% of the total nucleated cells) the cells presents distinct morphological features. 
The nucleus is large, retractile, contorted in shape, and contains small nucleoli. The 
abundant cytoplasm is arranged in processes of varying length and width and contains 
many large spherical mitochondria. In the living state, the cells undergo characteristic 
movements, and unlike macrophages, do not  appear to engage in active endocytosis 
(Steinman & Cohn, 1973). Further research revealed that these cells with versatile 
functions are widely distributed as immature cells within all tissues, particularly those that 
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interface with the environment (e.g. skin, mucosal surfaces) and in lymphoid organs 
(Wakabayashi, et al., 1997).  
Focusing on DCs functionality was started in 1979 by Steinman et al. when they obtained 
sufficient quantity of cells with high degree of purity from spleen. Functional studies 
became even more feasible since 1992 after development of new methods which enabled 
generation of large number of DCs from their progenitors in large numbers (Cella, et al., 
1997; Chapuis, et al., 1997; Shortman & Caux, 1997; Steinman, et al., 1979). 
Although antigens and lymphocytes (B cells, T cells, NK cells) have long been focused as 
the mediators of immune response, accumulating evidence demonstrate that DCs provide 
vital link between antigens and all type of lymphocytes. Several investigations persisted in 
different laboratories lead to the current acceptance that the most distinguishing feature of 
DC is its extraordinary ability to take up a nd present peptides and proteins to T and B 
lymphocytes. Therefore DCs are known as the most efficient antigen-presenting cells 
(APCS) which take up antigens and pathogens, generate MHC-peptide complexes, and 
migrate from the sites of antigen acquisition to secondary lymphoid organs and, finally 
physically interact with and stimulate T lymphocytes. These unique subsets of leukocytes 
which are equipped with an array of pattern recognition receptors for microbial structures, 
orchestrate the functional outcome of T cell activation by high expression of various co-
stimulatory molecules depending on t he type of DC presenting antigen and the 
physiological conditions in which DC: T cell interactions take place.  Indeed, these cells 
are the only antigen-presenting cells that induce the activation of resting T cells, both in 
vitro and in vivo. Besides eliciting immune response DCs are equally responsible for 
central and peripheral immune tolerance, which silences dangerous immune cells and 
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prevents them from attacking innocuous materials in the body or the body’s own tissue and 
also induce regulatory T cells that suppress the reactions of other immune cells. Thus, 
dendritic cells initiate adaptive immune responses and determine tolerance (Banchereau & 
Steinman, 1998; Y. Li, et al., 1997; Thery & Amigorena, 2001; Zanoni & Granucci, 2011). 
To do so, dendritic cells have developed unique membrane transport pathways. However, 
the molecular events controlling DC function are not yet fully understood and their 
transcriptional control of critical genes is an important new area (Connolly & Kusner, 
2007; Gatti & Pierre, 2003; Rolph, et al., 2006; Shklovskaya & Fazekas de St Groth, 
2007).   
2.2.1 Dendritric cells origins and subsets create functional complexity: Puzzels 
and paradoxes 
 
It was first believed that all DCs are derived from hematopoietic stem cells in the bone 
marrow, but it is also shown that many individual tissues generate their own DCs locally, 
from a reservoir of immediate DC precursors, rather than depending on a continuous flux 
of DCs from the bone marrow. Dendritic cells form heterogenous cell population can be 
broadly categorized based on the expression patterns of a number of cell surface markers 
into myeloid-derived, lymphoid-derived, dermal-derived, and plasmacytoid DC (Fig 2.1). 
DC should also be subdivided into migratory DCs, which reside in peripheral tissues, or 
lymphoid organ resident DCs (Hart, 1997).  
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Figure2. 1 A putative hematopoietic differentiation pathway for myeloid and lymphoid DC(Hart, 
1997) 
 
The presence of multiple DC subsets may be specialized for certain functions including 
induction of both immunological tolerance and effective immuno-stimulation as mentioned 
earlier.  However, the clear cut-cut view of functional specializing among DC subsets is 
unsustainable due to both functional diversity and plasticity of DC subsets. For example 
CD 8+  DCs in mice, display both immunoregulatory or tolerogenic induction ability, but 
also exhibit the strongest ability to induce T helper1 response by secreting high amounts of 
IL_12. In addition DCs exhibit great functional plasticity, which is induced by different 
tissue environments, response to different microbial stimuli or the duration of DC 
activation. So we have two distinct models, on one hand we have DC lineage model that 
suggest that phenotypically and functionally defined DC subsets happens early in 
hemopoesis, so that DC subsets develop as separate lineage with distinct functions and on 
the other hand functional plasticity of DC subsets represent different activation states or 
alternative cell fate of a single lineage dictated by local environment. Actually, expression 
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of a r ange of markers of heterogeneous DCs in human blood reflects differences in 
maturation or activation state of DCs, rather than delineating separate sub lineages. 
Functional plasticity of human DC subset when exposed to different cytokine or pathogens 
makes it d ifficult to assign a fixed function to a particular DC lineage (Ardavin, 2005; 
Arima, et al., 2010; Ito, et al., 2005).  
It should be mentioned that the developmental pathways that lead to the production of DCs 
are beginning to be understood. The existence of many specialized subtypes of DC has 
complicated this endeavor, as has the need to distinguish the DCs formed in steady state 
from those produced during an inflammatory response.  
Although the development of DCs from early hematopetic precusors is not fully 
understood, terminal stages of DC development and their life cycle during an immune 
response are well defined (Bharadwaj & Agrawal, 2007; Granucci & Zanoni, 2009) . 
2.2.2.1 In vitro generation of dendritic cells 
 
There are several models for generating dendritic cells from monocytes or CD34 +human 
stem cells and also generating plasmacytoid dendritic cells. However, blood monocytes are 
the most commonly used precursor cells for the generation of human DCs in vitro 
(Romani, et al., 1994; Thomas & Lipsky, 1994). 
It is known that monocytes can differentiate in the presence of the exogenous cytokines 
granolocyte macrophage colony stimulating factor (GM-CSF) and Interleukin-4 (IL-4) in 
to immature Dcs after 6 to 8 days (Kim, Hersh et al. 2003). These cells are shown to 
express characteristic surface markers such as MHC class I and II, CD 1a, CD 11b, CD 40, 
CD 80, CD 86 and CD 54 (i.e. ICAM-1).  
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Though, it is hypothesized that monocytes may also comprise a population of DC 
precursors, especially in inflammatory reactions. Thus, circulating monocytes, once 
recruited in to inflamed tissue, after taking up antigen, may develop in to DCs (Randolph, 
et al., 1999). Mast cells at inflammatory sites may provide a possible source for cytokines 
needed for the monocytes to differentiate (Mekori & Metcalfe, 2000). 
However, at this point DCs are easily available for cellular and molecular studies, it is  
unclear how much differentiation of monocytes into DC occurs in vivo compared with the 
differentiation of Mo-DC induced by cytokines in vitro  DCs. Indeed the correlation 
between the DCs generated in culture and naturally occurring DC subsets in vivo is not 
clear. 
2.2.3 Dendritic cells transformation from immature to mature state: Initiation 
of immune response 
 
DCs undergo three or more stages to become fully active APC: 
First, DCs are activated by variety of factors via TNF- α receptor super family and Toll-
like receptors (C. Brunner, et al., 2000; T. Kaisho & Akira, 2003).  
These stimulating factors can be:  
• Whole bacteria  
• Bacterial-derived antigens (e.g. lipopolysaccharide, LPS) 
• bacterial CpG DNA 
• Inflammatory cytokines and other activation signals received from the surrounding 
microenvironment 
• Ligation of select cell surface receptors (e.g. CD40)  
• Ligation of viral products (e.g. double-stranded RNA). 
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• Conversion of precursors of  l igands for nuclear receptors (PPARɣ , RA receptor, 
Vitamin D receptor and glucocorticoid receptor) to active hormones by DC itself 
Second, initial adhesion and antigen-specific recognition takes place. 
Third, full activation of DC via different signaling cascades, including activation of 
nuclear factor kappa B (NF-κ B), p38 mitogen activated kinase (MAPK) and c-Jun N-
terminal kinase (JNK) pathways (J. Y. Lee, et al., 2009; S. Li, et al., 2002).  T hese 
cascades are followed by costimulatory molecules activity and cytokine production. It 
should be mentioned that activated DCs have short life span, they undergo apoptosis in 
order to protect body from over stimulation (Banchereau, 2002) (Fig 2.2 & Figure 2.3).  
 
Figure2. 2 Life cycle of dendritic cells. Progenitors in bone marrow give rise to immature DCs 
with high phagocytotic potential that are recruited to tissues. Upon antigen uptake, cells 
migrate to lymphoid organs and mature to potent immunostimulatory antigen presenting cells 
(Banchereau, 2002). 
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Figure2. 3 The type of signal that leads to DC activation influences the outcome of immune 
responses 
 
 It is now clear that the maturation of DCs is crucial for the initiation and regulation of 
immunity while in most tissues, DCs are present in a so-called ‘immature’ state and are 
unable to stimulate T cells. Although these DCs lack the requisite accessory signals for T 
cell activation, such as CD40, CD54, CD80 and CD86, they are extremely well equipped 
to capture Ags in peripheral sites. Immature DCs have features other than phagocytosis  
that allow them to capture picomolar and nanomolar concentration of Ag, much less than 
the micromolar levels typically required by other APCs. They also express receptors that 
mediate adsorptive endocytosis, including lectin receptors like the macrophage mannose 
receptor and DEC-205, as well as Fcg and Fce receptors which function very effectively in 
immature DCs. However, once DCs have captured Ags, their ability to capture more Ag 
rapidly declines (Bharadwaj & Agrawal, 2007; Granucci & Zanoni, 2009; Zanoni, et al., 
2009).  
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DCs are able to produce large amounts of MHC class II-peptide complexes. This is due to 
the specialized, MHC class II rich compartments (MIICs) that are abundant in immature 
DCs. During maturation of DCs, MIICs convert to non-lysosomal vesicles and discharge 
their MHC-peptide complexes on to the cell surface. As mentioned earlier the maturation 
of DCs is completed only upon interaction with T cells which is characterized by loss of 
phagocytic capacity and expression of many other accessory molecules such as LFA-
3/CD58, ICAM-1/CD54, B7-1/CD80, B7-2/CD86 and CD83 that interact with receptors 
on T cells to enhance adhesion and signaling. Expression of one or both of the 
costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on the DCs are essential for the 
effective activation of T lymphocytes, and for IL-2 production.  Other phenotypical and 
functional changes of DCs during the process of conversion from immature to mature state 
are summarized in table 2.21.  
 
Figure2. 4 Example of Regulation of Immune Responses by Dendritic Cells 1. Immature dendritic cells can 
endocytose Antigen. 2. Maturation of dendritic cell as it travels toward the secondary lymphoid compartment is 
heralded by presentation antigen on DC surface. 3. Mature DC presents antigen to naïve T cells, stimulating 
generation of CTLs 4. Th1 lymphocytes are produced by DCs secreting IL-12. Th1 cells activate CTLs by secreting a 
range of cytokines, including IL-2 and IFN-.. 5. However, DCs which secrete IL-10 will stimulate production of Th2 
cells. Th2 responses are characterised by secretion of IL-10, IL-4 and IL-5. These cytokines down-regulate cell 
mediated immune responses. 6. Stimulation of Treg cells by DCs further down-regulates cell mediated immunity due 
to secretion by Treg cells of IL-10 and Transforming growth factor (TGF-ß). 7. Th1 responses are characterised by 
stimulation of cell-mediated immune responses and enhanced tumour cell killing. 8. Th2 and Treg effects, however, 
lead to T cell anergy and tolerance of tumour cells (McKechnie, et al., 2004)  
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Table2.2 1 Phenotypic and functional changes of DCs in immature and mature state 
 
Characteristics of immature dendritic cells Characteristics of mature dendritic cells 
High intracellular MHC II in the form of  MIICs Morphological change: formation of dendrites 
Expression of CD1a 
Motility: Active process formation and 
movement 
High expression of chemokine recptors CCR1, 
CCR2,CCR5,CCR6 and CXCR1 
Change in expression of CCR6 and CCR7 
Antigen capture: Macrophage mannose receptor 
(MR),type 1c- type lectin redeptor( DEC-205) type 
II C-type lectins important for receptor-mediated 
antigen uptake include DC immunoreceptor, DC-
associated C-type lectin-2 and C-type lectin 
receptor 1 
DCIR, MR, and FceR are all down-regulated 
upon DC maturation, further emphasizing their 
specific roles in antigen uptake in immature 
DCs 
Active endocytosis for certain particulates and 
proteins; presence of FcgR and active 
phagocytosis 
 
Deficient T cell sensitization in vitro 
Antigen presentation: High MHC class I and II 
expression 
Low/absent adhesive and costimulatory molecules 
(CD40/54/58/80/86) 
Abundance of molecules for T cell binding and 
costimulation, (e.g. CD40, CD54/ICAM-1, 
CD58/LFA-3, CD80/B7-1 and CD86/B7-2) 
Low/absent CD25, CD83, p55, D EC-205, 
2A1antigen 
Cytokines: Abundant IL-12 production; 
resistance to IL-10 DC-restricted molecules: 
p55, CD83, S100b 
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2.2.4 Dendritic Cell and expression of CD markers 
 
There is no s ingle universally accepted hallmark of dendritic cell activation. Instead a 
variety of methods are used to identify APCs and assess their activation state. One of these 
activation measures includes phenotypic methods by assessing the increased expression of 
surface markers.  
The cluster of differentiation (CD) is a protocol commonly used for the identification and 
investigation of cell surface molecules present on blood cells. CD molecules can act in 
numerous ways, often acting as receptors or ligands or have other functions, such as cell 
adhesion. These markers are often used to associate cells with certain immune functions or 
properties. While using one CD molecule to define populations is uncommon, combining 
markers has allowed for cell types with very specific definitions within the immune 
system. CD molecules are utilized in cell sorting using various methods including flow 
cytometry (Zola, et al., 2007). 
Differentiated dendritic cells are CD80+, CD86+, CD83+, CD54+, CD1a+, CD11b+, 
CD11c+, HLA-DR+ , CD34-, CD3-, CD19-, CD14-, and CD16-. 
2.2.4.1 CD 11c 
 
CD11c a member of the leukointegrin family, is expressed on the plasma membranes of 
monocytes, tissue macrophages, NK cells, and most dendritic cells (Ruedl, et al., 1996). As 
a result of its high level of expression on most DCs, CD11c is considered a marker of these 
dedicated APC(Metlay, et al., 1990). Although involvement of CD11c in diverse functions 
of DC is relatively unexplored, its role in antigen presentation has been revealed by some 
studies (Meunier, et al., 1994). 
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2.2.4.2 CD 14 
 
CD14 is a surface antigen expressed strongly on monocytes and is anchored to the cell 
surface by linkage to glycosylphosphatidylinositol(Tobias, et al., 1993). Cytokines such as 
GM-CSF and IL-4 encourage Cd14+ monocytes to differentiate to dendritic cells 
(Verhasselt, et al., 1997). CD14 alone is shown to be sufficient and necessary to regulate 
the dendritic cell life cycle after LPS exposure through nuclear factor of activated T cells 
(NFAT) pathway (Zanoni, et al., 2009). Indeed, CD14 acts as a co-receptor along with 
TLR 4 and MD-2 for the detection of bacterial lipopolysaccharide. Apart from binding 
LPS, CD14 has been shown to bind peptidoglycan of Gram-positive bacteria (Pugin et al, 
1994) and other pathogen-associated molecular patterns thus mediate the innate immune 
response (Heumann et al, 1998). Blocking of  CD14 with monoclonal antibodies prevented 
synthesis of TNF-α by whole blood incubated with LPS (Wright, et al., 1990).    
2.2.4.3 CD 54 
 
CD54 also known as Inter-Cellular Adhesion Molecule 1 (ICAM-1) is trans-membrane 
protein long known for its importance in stabilizing cell-cell interactions and facilitating 
leukocyte endothelial transmigration. CD54, by virtue of its biological role, is an 
appropriate candidate as both a phenotypic marker of APCs as well as an indicator of their 
activation state, thereby strengthening the interface of the immunological synapse between 
an APC and a T cell  (Lebedeva, et al., 2005).  
Direct role of CD54 for APC functionality, in terms of activating or priming T cells, is 
substantiated by a number of murine studies that show an absence of CD54 expression on 
APCs leads to lowered T cell activation of naïve T cells (Padros, et al., 1992) or 
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functionally impaired  memory T cells. Its expression can be stimulated by IFN-gamma, 
TNF-alpha, IL-1 beta and LPS. CD 54 possesses binding sites for a number of immune-
associated ligands (Sheikh & Jones, 2008).  
2.2.4.4 CD 80  
 
Co-stimulatory molecule CD80 also known as B7.1 is a member of the immunoglobulin 
(Ig) superfamily, was the first ligand to be identified for CD28  (Mochizuki, et al., 1997). 
CD 80 e xpression is almost exclusively restricted to lymphoid tissues, primarily on 
professional antigen presenting cells (Villarroel-Dorrego, et al., 2005). 
CD 80 provides similar costimulatory signals as CD 86 for T cell proliferation, cytokine 
production, and generation of T cells.  However, studies have shown that CD80 blockage 
has negligible effects on T-cell responses while CD86 blockage has detrimental effects on 
T-cell activation (Dilioglou, et al., 2003; Manickasingham, et al., 1998). Indeed, it has 
been suggested that the presence of CD80 favors the activation of Th1 lymphocytes, 
whereas CD86 favors priming of Th2 cells (Freeman, et al., 1995). 
2.2.4.5 CD 83 
 
CD83 is a membrane glycoprotein belonging to the Ig superfamily and it has been known 
for decades to be one of the best and typical markers of fully mature dendritic cells (Zhou, 
et al., 1992). Central role of CD 83 in cell-mediated immunity has been conserved for over 
450 million years of vertebrate evolution (Ohta, et al., 2004). 
The fact that CD83 is strongly upregulated together with co-stimulatory molecules such as 
CD80 and CD86 during DC maturation suggests it plays an important role in the induction 
of immunostimulatory as well as regulatory effects (Lechmann, et al., 2002). CD 83 i s 
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recognized to be essential molecule for CD 4+T cell generation. Indeed, when CD 83 is up-
regulated by activation, the soluble form of CD 83 is released from the activated cells and 
this soluble form has inhibitory function within the immune reactions. Downstream 
transcription unit for CD83 is known to be triggered by Nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) and that this signaling pathway plays a crucial role 
during the induction of an adaptive immune response (McKinsey, et al., 2000). 
2.2.4.6 CD86 
 
CD 86 is a type I membrane protein also known as B7.2. Its expression on hematopoietic 
progenitor cells is regulated by TNF-α and denotes differentiation towards the macrophage 
or dendritic cell lineages. Expression of CD 86 on dendritic cells along with CD80 (B7.1), 
provide the necessary stimuli for priming T cells by binding to CD 28. Up regulation of 
CD86 expression is a hallmark of dendritic cell activation and maturation. It is shown that 
IL-10 inserts its inhibitory effect through down-regulation of B7-2 expression at DC 
surface (Buelens, et al., 1995). 
Over expression of CD 86 on de ndritic cells in systematic autoimmune disease such as 
systemic lupus erythematosus may explain how the peripheral tolerance is broken in these 
conditions (Decker, et al., 2006) 
2.2.4.7 CD 209 (DC-SIGN) 
 
Dendritic cell-specific ICAM-3 grabbing non-integrin (DC-SIGN) is a type II 
transmembrane protein that based on its structure, belongs to the C-type lectin family. DC-
SIGN is a specific adhesion receptor expressed on precursors in blood and on immature 
and mature DCs in both peripheral and lymphoid tissues (Soilleux, 2003). CD 209 is also 
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essential in several key functions throughout the life cycle and is central to the unusual 
trafficking capacity of DCs (Turville, et al., 2003). It takes up, processes pathogens and 
mediates strong adhesion between DC to ICAM-3 on resting T cells by stabilization of the 
DC–T cell contact zone, thus is essential for DC–T Cell Clustering and DC-induced T cell 
proliferation(Geijtenbeek, et al., 2000).  
 
2.2.5 Dendritic Cells and  Cytokines Production 
 
Dendritic cells are a major source of many cytokines, namely, IFN-α, IFN-ß, IFN-ɣ , IL-
1α, IL-1ß, IL-4, IL-6, IL-7, IL-10, IL-12, IL-15, IL-16, IL-17, TNF-α and also produce 
macrophage inflammatory protein (MIP1g), all of which are important in the elicitation of 
a primary immune response. The soluble cytokine profile secreted by DCs varies with the 
different stages of DC development and maturation and not necessarily simultaneously 
thus influencing the different effector functions characteristic of immature vs. mature DCs. 
Also, there is evidence that the cytokine secretion pattern of the plastic-adherent 
monocyte-derived DCs (grown in GM-CSF and IL-4) can be induced along the Th1 (IL-
12) or Th 2 (IL-10) cytokine secretory pathway.  
 2.25.1)  IL-10 
 
IL- 10 also known as human cytokine synthesis inhibitory factor (CSIF), is an anti-
inflammatory cytokine. Most of the immunosuppressive effects of interleukin-10 (IL-10) 
are related to functional inhibition of antigen-presenting cells. It is well known that IL-10 
has an important regulatory role on m onocytes function and on D C maturation (Corinti, 
Albanesi et al. 2001). Dendritic cells, grown and matured in vitro, can synthesize IL-10 in 
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a continuous manner. It is also well established that CD14+ DCs of myeloid origin 
synthesize IL-10 as do monocytes and macrophages.  
Dendritic cells secreting IL-10 exhibit minimal or no stimulatory properties and are 
markedly inhibitory to T cell proliferation induced by polyclonal activators. Thus, IL-10 
producing DCs are functionally and phenotypically inhibitory accessory cells and 
putatively tolerogenic. Moreover, IL-10 significantly inhibits ability of APCs to synthesize 
IL-12. It inhibits synthesis of pro-inflammatory cytokines like IFN-γ and TNF-α. However, 
it is also stimulatory towards certain T cells, mast cells and B cells (Chen, et al., 2007; 
Corinti, et al., 2001; Demangel, et al., 2002). 
2.2.5.2) IL-12 
 
Interleukin 12 (IL-12) is naturally produced by dendritic cells macrophages, monocytes, 
and B cells and is an important regulatory cytokine that has a function central to 
the initiation and regulation of cellular immune responses notably by inducing T and NK 
cells to produce IFN- .  Though, researchers believe that immunological action of IL-12 
must be directed primarily to those cells that are capable of producing IFN-ɣ .  Moreover, 
IL-12 is responsible primarily for the subsequent production of TNF-α from both NK cells 
and helper T cells.   
IL-12 has the capacity to regulate the differentiation of naive T cells into TH1 cells, which 
is crucial in determining resistance and the type of response that will be elicited in 
response to a particular pathogen.  It stimulates the growth and function of T cells and 
alters the normal cycle of apoptotic cell death. The most powerful inducers of IL12 are 
bacteria, bacterial products, and parasites (Muller-Berghaus, et al., 2005; Wesa & Galy, 
2001).  
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2.2.5.3) IFN-γ 
 
IFN-γ is the sole type II interferon produced by B cells, NKT cells, and professional APCs 
that participates in the control of the innate and adaptive phases of the immune response 
(Frucht, et al., 2001). Indeed, IFN-γ production by professional APCs acting locally may 
be important in cell self-activation and activation of nearby cells.  IFN-γ exerts most of its 
effects on APCs; it activates macrophages and polarizes immature DCs into Th1 cell–
promoting effector DCs (Vieira, et al., 2000).   
In addition to acting on mature APC functions, interferon γ can orchestrate immune 
response by switching monocyte differentiation from DCs to macrophages (Delneste, et 
al., 2003). IFN-γ–activated macrophages exhibit potent bactericidal and antitumor 
activities.  
IFN-γ coordinates a diverse array of cellular programs through transcriptional regulation of 
immunologically relevant genes. Production of IFN-γ itself is controlled by cytokines 
secreted by APCs, most notably IL-12 as mentioned earlier. IFN-γ also acts on DCs to 
augment IL-12 secretion. Thus, IL-12 and IFN-γ comprise a positive feedback system and 
plays a major role in the clearance of intracellular pathogens  Negative regulators of IFN-γ 
production include IL-4, IL- 10, transforming growth factor and glucocorticoids (Pan, et 
al., 2004). 
2.2.5.4) TNF-α 
 
TNF-α is a cytokine involved in regulation of immune cells. It is able to induce systemic 
inflammation and apoptotic cell death. TNF-α is a member of a group of cytokines that 
stimulate the acute phase reaction and is well recognized for its role in mediating innate 
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immune responses.  A lso TNF-α appears to have profound effects on DC function, as it 
contributes to their activation, maturation, migration, accumulation within draining lymph 
nodes, and significantly reduces IL-10-mediated inhibition of DC development and 
function.  Inhibition of TNFα activity during dendritic cell maturation has been shown to 
lead to the development of semi-mature cells (van Lieshout, et al., 2005). All these 
functions indicate the importance of this innate cytokine in activating adaptive immunity to 
viral challenge. TNF-α is mainly secreted by macrophages, monocytes, neutrophils, T-
cells, NK-cells following their stimulation by bacterial lipopolysaccharides (Christoph 
Brunner, et al., 2000; Trevejo, et al., 2001). 
 
TLRs are germline-encoded receptors with high sequence homology expressed by cells of 
the innate immune systems that recognize 
2.2.6 Toll-like receptors (TLRs) 
pathogen-associated molecular patterns 
(PAMPs) (Akira, et al., 2006). Thirteen TLRs (named simply TLR1 to TLR13) have been 
identified in humans and mice together.  It is becoming increasingly evident that TLR 
regulate all major phases of the immune response. Stimulation of TLRs strongly activates 
DCs to up-regulate co-stimulatory molecules (CD80 and CD86) and to produce pro-
inflammatory cytokines (TNF-α, IL-6, and IL-12) though causes an immediate defensive 
response (Tsuneyasu Kaisho & Akira, 2001; Thoma-Uszynski, et al., 2000). Accumulating 
evidence has shown that individual TLRs can activate overlapping as well as distinct 
signaling pathways, ultimately giving rise to distinct biological effects (Zhang, et al., 
2008). The first evidence that  show cytokine gene expression is differentially regulated by 
the various TLR was obtained from studies using mouse macrophages (Hirschfeld et al., 
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2001) and human(Re & Strominger, 2001). For instance TLR2 and TLR4 although both 
led to comparable activation of NFκb and mitogen activated protein kinase family 
differentialy activate human DCs. Though, the observed patterns of gene induction of 
TLRs predict differential polarization of adaptive immune responses. Moreover, distinct 
TLRs act in synergy and cooperate with other PRPs resulting in coordinated sum of signals 
(Napolitani, et al., 2005; Sato, et al., 2000).  However, it is shown that TLR4 can even 
activate intracellular signaling pathway without the need of other TLRs.(Kokkinopoulos, et 
al., 2005). 
Investigation of TLR gene expression helps to understand how immune cell responses to 
bacteria are controlled.  It is believed that expression of TLR is tightly regulated and 
differs between DC populations at different anatomical sites (Iwasaki & Medzhitov, 2004). 
Still there is little known regarding the regulation of TLR gene expression in DCs.  
 
2.2.6.1 TLR4 
 
TLR4 is a r eceptor for Gram_ LPS, respiratory syncytial virus protein F, and other 
endogenous ligands, such as surfactant protein A and fibronectin fragment. There are 
controversies with regard to expression of TLR4 in DCs. Some have reported that TLR4 is 
not expressed in monocyte derived dendritic cells whereas there are reports which indicate 
some expression levels in these DCS (Muzio, et al., 2000; Thoma-Uszynski, et al., 2000).  
Indeed, it is shown that TLR4 and its agonists are capable of inducing DC maturation as 
measured by the up-regulation of several cell surface markers such as CD40, CD86, HLA-
DR, and CD83 (Re & Strominger, 2001). TLR4 deficient mice showed 
hyporesponsiveness to LPS, demonstrating that TLR4 is a critical receptor for LPS 
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signaling. Indeed, it is shown that LPS stimulation increase TLR4 expression in mouse 
immature DC significantly (An, et al., 2002) 
TLR4 agonist specifically promotes production of the TH-1 inducing cytokine interlukine 
12 and the chemokine interferone gamma which is also associated with TH-1 responses 
(Re & Strominger, 2001).   
Inflammatory signaling pathways are induced by activation of NF-kB and MAPK family 
members after ligation of stimulants to TLR4.  On the other hand, it is also shown that 
inhibition of NFκb and p38 kinase prevented upregulation of TLR-4 gene expression by 
LPS.  
Moreover, it is  said that transcription of several chemokine genes stimulated by TLR4  
rapidly fades in cells thus TLR4 stimulation leads to transient responses than other TLRs 
as TLR2 (Re & Strominger, 2001).. 
2 .2.7 P38 mitogen-activated protein kinase 
 
Mitogen-activated protein (MAP) kinase pathways are one of the intracellular signaling 
pathways that mediate cellular behavior in response to extracellular stimuli.  In fact, MAP 
kinases are members of discrete signaling cascades and serve as focal points in response to 
a variety of extracellular stimuli such as cytokines (TNF-  & IL-1), growth factors, 
ultraviolet irradiation, heat shock, and osmotic shock, and are involved in cell 
differentiation and apoptosis(Raingeaud, et al., 1995). This plethora of activators conveys 
the complexity of the p38 pa thway and this matter is further complicated by the 
observation that activation of p38 i s not only dependent on s timulus, but on cell type as 
well.  Four distinct subgroups within the MAP kinase family have been described: (1) 
extracellular signal-regulated kinases (ERKs), (2) c-jun N-terminal or stress-activated 
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protein kinases (JNK/SAPK), (3) ERK/big MAP kinase 1 (BMK1), and (4) the p38 group 
of protein kinases.  
We have selected p38 for our study. The downstream targets of the p38 MAPkinases 
include a w ide array of cytoplasmic and nuclear factors. Cellular response to stress 
activation depends upon the activity of each specific p38 isoform and cell context (Zarubin 
& Han, 2005). 
P38 has shown different roles in the LPS response of DC. Inhibition of p38 ki nase has 
been shown to prevent LPS-induced production of a variety of cytokines in DC and 
suppress LPS- induced TLR-4  messenger RNA (mRNA) increase (An, et al., 2002) . 
2.2.8 Iκb 
 
IκB is family of inhibitory proteins which with their multiple forms appear to regulate NF-
κ B by distinct mechanisms at primary level. The transcription factor NF-κ B is generally 
present in an inactive cytoplasmic form, bound to inhibitory IκB proteins. Activation of 
NF-κ B to move into the nucleus is controlled by the targeted phosphorylation and 
subsequent degradation of I kappa B(Baldwin, 1996). Cell stimulation causes its 
dissociation and translocation of active NF-κ B to the nucleus. NF-κ B can be activated by 
exposure of cells to LPS or inflammatory cytokines such as TNF-α or IL-1, viral infection 
or expression of certain viral gene products, UV irradiation, B or T cell activation, and by 
other physiological and non-physiological stimuli. 
NFκb activation is essential for the expression of a variety of cytokines in the LPS 
response. NFκb inhibitors are shown to inhibit LPS-induced NFκB p65 s ub unit nuclear 
translocation as well as up-regulation of TLR4 mRNA suggesting that NFκb pathway is 
important in the regulation of TLR expression in DC (Tsuneyasu Kaisho & Tanaka, 2008). 
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2.2.9 miRNA 
 
micro RNAs (miR) are small non coding single stranded RNAs of about 18-24 nucleotides 
length that are highly conserved during evolution. They have recently emerged as potent 
regulators of gene expression after transcription level (Bartel, 2004). Just like other RNAs, 
miR sequences are anchored in the DNA and get transcribed. Approximately 500 genes 
encoding miRNAs have been identified in mammals which are shown to be both 
temporally and spatially regulated. miRNAs play pivotal roles in shaping cellular 
development and differentiation in various tissues including immune cells. In the immune 
system, miRNAs act at check points during hematopoietic development and cell subset 
differentiation, they modulate effector cell function, and they are implicated in the 
maintenance of homeostasis (Figure 2.5),(Mark A, 2008; Turner, et al., 2011).  miRs have 
the ability to “cleave” to their target-mRNA and in this way block the translation or they 
elicit target mRNA degradation, thereby the mRNA cannot be translated into the protein 
structure and degrades. Clearly, this process is a post-transcriptional modification, with the 
effect that the protein is not built and the cellular response is changed (Chekulaeva & 
Filipowicz, 2009).  No doubt, deregulated miRNA levels can lead to several types of 
malignancies and autoimmune conditions.  
Recently the miRNA content of DC’s at different functional states have been profiled, and 
they can be utilized as potential novel biomarkers. Indeed, distinct miRNA profile can be 
also used for separation of mature and tolerogenic DCs(Kuipers, et al., 2010). 
miR-155 and miR-146a are among the validated miRNAs expressed in DCs , however, 
their role  in dendritic cell biology has not been well studied in depth yet. 
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Figure2. 5    Role of microRNAs (miRNAs) in the regulation of the immune response. The illustration summaries 
what is know of the mechanism by which individual miRNAs (red boxes) interact with transcription factors (green 
circles) and other proteins (yellow boxes) to regulate cell responses (blue circles) during immune cell development 
and the innate (monocytes, macrophages and neutrophils) and acquired (B and T cells) immune response. 
Stimulation (↑) or inhibition ( ⊤) should be determined by following how the changes in the individual miRNA 
expression (red squares) impacts on the indicated biological response (blue circles). AML, acute myeloid leukaemia; 
AP-1, activator protein; BCR, B-cell receptor; C/EBP, CCAAT-enhancer binding protein; DUSP, dual specificity 
phosphatase; IGFR, insulin-like growth factor receptor; IRAK, IL-1 receptor activated kinase; JNK, c-jun N-terminal 
kinase; M-CSF, macrophage colony stimulating factor; Maf, musculoaponeurotic fibrosarcoma: Mef, myeloid ELF-1 
like factor; NF, nuclear factor; PTEN, phosphatase and tensin homolog; PTP, protein tyrosine phosphatase; RA, 
retinoic acid; SHP, Steroid Receptor Coactivator (Src) homology 2 domain–containing protein-tyrosine phosphatase; 
TCR, T-cell receptor; TLR, Toll-like receptor; TNF Associated Receptor Factor (TRAF), TNF receptor-associated factor 
(Mark A, 2008). 
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2.2.9.2 miRNA146a 
 
miRNA146a is known as a novel negative regulator that helps to fine-tune the immune 
response. Its expression is shown in macrophages and alveolar/bronchial epithelial 
following activation of TLR-2, TLR -4 and TLR -5 or exposure to TNFα and IL-1β. 
Indeed, miRNA146a is shown to regulate the maturation process and pro-inflammatory 
cytokine secretion in DCs as well.  Later it became clear that miRNA 146a directly control 
TLR4 and cytokine signaling through NFκB pathway by targeting  Interleukin-1 receptor 
associated kinase (IRAK1), Interleukin-2 receptor associated kinase (IRAK2) and TNF 
receptor-associated factor 6 (TRAF6), (Konstantin D. Taganov, et al., 2006). Such findings 
demonstrate that miRNAs levels can be altered by bacterial endotoxin and thereby 
involved in regulating innate immune responses.  Moreover, changes in the expression of 
miR-146a are found as important event in the pathogenesis of many human diseases, 
including autoimmune disorders such as rheumatoid arthritis (RA), systemic lupus 
erythematosus, psoriasis(Pauley, et al., 2008).  
2.2.9.3 miRNA 155 
 
In contrast to miR-146a, miRNA-155 seems to positively regulate the release of inflammatory 
mediators during the innate immune response. Its own expression is  a lso induced by 
inflammatory signals such as exposure to antigen, Toll-like receptor ligands and 
proinflammatory transcription factors such as NF-κB (O'Connell, et al., 2007). An increase 
in miR-155 levels during maturation of human monocyte-derived dendritic cells after 
exposure to LPS is demonstrated. More evidence on the role for MAPK signaling elements 
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in the regulation of miR-155 levels has been increasingly emerged. Indeed, miR-155 
knock-out mice show aberrant immune functions including abnormal function of APCs. In 
a further study, inhibiting miR-155 has shown to impaire pathogen binding capacity by 
increasing DCSIGN.  So DC-SIGN, a protein of functional importance in the immune 
system, is regulated indirectly by miR-155 (Rocio T. Martinez-Nunez, et al., 2009).  
2.3 Interaction of Lactobacillus with the Immune System                
                                
During the 1990s growing interest was focused on the effect of LAB on specific and non-
specific immune functions. Certain strains were found to enhance phagocytosis, secrete 
lysosomal enzymes and reactivate oxygen species (Gill, et al., 2000). Some strains as 
Lactobacillus  GG were shown to be able to  increase the  i mmunogenicity of an oral 
rotavirus vaccine (Isolauri, et al., 1995),  a nd several strains of mainly lactobacilli were 
found to induce pro- or anti-inflammatory response (Hessle, et al., 1999).  Gradually strong 
evidences were found that probiotics adhesion to endothelial cells is not necessary for 
induction of immune stimulation. Also not only live strains but even heat-killed L.casei 
and L. fermentum, lipoteichoic acid (LTA) and crude cell extracts, likewise induced a 
proinflammatory response in the form of TNF-α in a macrophage cell line (Morita, et al., 
2002; Wehkamp, et al., 2004). On the other hand, a mixture of 3 strains, L.acidophilus, L 
delbrueckii ssp bulgaricus and B. bifidum was reported to induce a predominant anti-
inflammatory response in monocytes (Michalkiewicz et al., 2003). Oral administration of 
L. rhamnosus, L. acidophilus or B. lactis was able to enhance the  immunoreactivity of 
spleen cells and phagocytes, and enhance serum antibody response to orally and 
systemically administered antigens (Gill, et al., 2000). Oral administration of L. rhamnosus 
GG for 4 weeks to atopic children resulted in a significant elevation of the serum 
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concentration of IL-10 and was later confirmed in a placebo-controlled trial (Kalliomaki, et 
al., 2001; Pessi, et al., 2000).  
In DCs all tested strains of lactobacilli induced DC maturation and cytokine production 
(Christensen, et al., 2002). Indeed, VSL#3, a probiotic cocktail containing 8 di fferent 
strains of Bifidobacterium and Lactobacillus sp and St salivarius ssp thermophilus resulted 
in substantial production of IL-10 in DCs (Drakes, et al., 2004)  
The identification of the underlying mechanisms is crucial for new credence for the use of 
probiotics in clinical medicine. 
 
2.4 The probiotics paradox: live and dead cells both are biological response 
modifiers 
 
The probiotics paradox is that both live and dead cells in probiotic products can generate 
beneficial biological responses even if they didn’t meet the WHO definition of probiotics 
as being viable. This has become an ongoing debate as some strains are found to be 
effective only in  viable form as  L.salivarius ssp.salivarius , while products based on dead 
cells or cell fractions have been demonstrated to be effective as well (Kataria, et al., 2009). 
For example killed Lactobacillus has been shown to inhibit adherence of gastrointestinal 
pathogens to epithelial cells (Coconnier, et al., 1993). Orally administered cell wall 
preparations stimulate the gut immune system (Sakai, et al., 2011). Killed Enterococcus 
faecalis cells have been shown to stimulate the bone narrow(Hasegawa, et al., 1996). Live 
and heat treated Lactobacillus rhamnosus have been shown to be effective in reducing the 
inflammatory response in the gastrointestinal tissue (N. Li, et al., 2009). Similarly, heat 
killed Bifidobacterium was effective against ulcerative colitis (Imaoka, et al., 2008). 
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Moreover, the biological response to dead probiotic cells was shown to be similar to an 
oral immunization response from a killed vaccine (Adams, 2010). Hence, many effects 
obtained from viable cells of probiotics are also shown to be obtained from populations of 
dead cells.   
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3. Methods & Materials  
3.1 Probiotics 
3.1.1. Probiotics Strains 
 
Lactobacillus rhamnosus GG (ATCC-53103) and Lactobacillus delbrueckii subsp. 
Bulgaricus (ATCC-11842) are the applied probiotics in this study purchased from LGC 
standards GmbH (Germany). 
3.1.2 Thawing and Preparation of Probiotics  
 
One aliquot (1000µl) of each strains were thawed and centrifuged with 3000* r cf for 5 
minutes and were washed three times with Phosphate buffer saline (PBS) in order to 
remove the glycerol which had been added for freezing. 
3.1.3 Culturing and counting strains 
 
Eight dilutions of each strain were made after resuspending them thoroughly in 1000µl of 
PBS (PAA- laboratories, Austria) and two plates were cultured from each dilution using 
MRS agar (deMan, Rogsa sharp Agar, LAB 93, U.K) . Plates were incubated (CO2: 5%, 
temperature: 37 c) for 48 hrs. After wards, the mean CFU were calculated by counting the 
CFUs for each dilution at logarithmic phase. The second calculation was performed by 
culturing three plates from the countable dilutions. The mean of two calculations were 
considered as the strains population in 1000µl medium. 
3.1.4 Heat inactivation 
 
Autoclaving was selected for heat inactivation of probiotics as the strains particularly 
lactobacillus delbrueckii resisted to heat inactivation protocols using either 90 c for 15 min 
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or 100c for 45 min as mentioned in the available publications.100 µl of each strain were 
cultured on three plates after applying each protocol of heat inactivation to make sure no 
colony is growing. 
3.1.5 Preparation for co culture 
 
 One aliquot of heat inactivated probiotics were thawed and centrifuged (350* g) to remove 
the PBS and complemented RMPI (RPMI+ FCS 10% + glutamine) was added to reach 1ml 
volume. 
3.2 Dendritic Cells 
3.2.1. Blood collection and Peripheral Blood Mononuclear cells (PBMC) isolation 
 
64 ml blood was collected in 8 ml heparin containing tubes from 4 healthy volunteers in 
fasting state. Bloods were centrifuged for 10 m in (623 *rcf, break 0, 18c). Serums were 
pumped out and the remaining bloods were diluted with sterile warm RPMI (PAA 
Laboratories, Austria), and were resuspended carefully to become completely 
homogenized. The diluted bloods were added slowly to ficoll tubes (Ficoll Paque Plus, GE 
Healthcare, Vienna, Austria) and centrifuged with slower speed (318*g; 30 m in; 18 c; 
brake 0) to reach the buffy ring  of  lymphocytes (Figure3.1).  The ring was harvested 
carefully and collected in tubes containing RPMI and Centrifuged ( 318*g; 30 min; 18c; 
brake 9). After washing the cells for the second time with RPMI the cells were collected in 
a single tube and counted by invitrogen countess automated cell counter. 
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Figure 3. 1   Peripheral blood mononuclear isolated from whole blood by Ficoll-Hypaque centrifugation. 
Diluted anticoagulated blood (left panel) is layered over Ficoll-Hypaque and centrifuged. Red blood cells and 
polymorphonuclear leukocytes or granulocytes are more dense and centrifuge through the Ficoll-Hypaque, while 
mononuclear cells consisting of lymphocytes together with some monocytes band over it and can be recovered at the 
interface (right panel). 
3.2.2 Monocyte isolation using Dyabeads (Invitrogen) 
 
After centrifuging the cells for 10 m in and pumping out the supernatant, the cells were 
washed with isolation buffer (Ca and Mg free phosphate buffered saline supplemented 
with 0.1%  Bovine Serum Albumin (BSA)  and 2ml Ethylenediamine Tetraaceticacid 
(EDTA) and the RPMI was removed.  T he further steps were performed in 2-8°C 
according to the cell number following the  the Dynabeads untouched Human Monocytes 
kit protocol  (Dynabeads, MyPure Monocyte Kit 2, Invitrogen, Lofer, Austria), (Appendix 
I). 
3.2.5 Differentiation to DC 
 
To  g enerate  i mmature monocyte  de rived DCs  (Mo-DC), negatively  isolated  
monocytes  were  cultured at a cell  density  of   5×105 cells/ml in cell culture medium, in 
the presence of recombinant IL-4 (100 ng/ml) (Invitrogen, GmbH)  and  recombinant  
GM-CSF  (10 ng/ml) (Invitrogen, GmbH)  for  6-7  days. Then the cells were 
distributed in 6 well plates (Iwaki 3810-006, Japan) according to the achieved cell number 
and 2ml complemented RPMI was added to each well and the cells were incubated 
overnight. After one night 10 µl of IL-4 and GMCSF   w ere added to each 1ml of cell 
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suspension. Every other day half of the medium were removed and exchanged with new 
medium containing the same cytokines until day 7. 
3.2.6 Coculturing probiotics with immature DC 
 
On 7th day the immature DCs were scrapped off from the wells using cell scrapper. After 
DCs were counted they were co cultured with lactobacillus Rhamnosous and delbrueckii in 
ratio of 10:1 and 100:1 (CFU: DC) and incubated for 24 hour s. LPS (Sigma –Aldrich 
Handels, GmbH) was used as the positive control. 
 
3.3 Fluorescence – Activated Cell Sorter (FACS) analysis 
3.3.1 Harvesting and staining of cells for FACS analysis: Cluster of 
differentiation (CD) markers measurement 
 
The cells were scrapped off the wells, collected in separate tubes and were centrifuged for 
30 min at 250 r cf. The supernatants were removed and stored as 500µl aliquots in -20c 
freezer for cytokine measurement. 
Dendritic cells were washed twice with PBS and centrifuged for 5 min at 250*g. As we 
had 4 antibodies and 100µl of cell suspension was needed for each antibody tube the cells 
were finally resuspend in 400µl PBS and 5µl of antibodies were added (Table 3.1) 
 The tubes were vortexed and incubated for 25 min in refrigerator. At the next step the 
stains were washed twice with 2ml stain buffer and centrifuged for 5 minutes at 3000 *g 
while avoiding light exposure. The cells were prepared for FACS analysis by adding 200 
to 300 µl stain buffer to each tube. 
Cells were measured using a 4 -color BD FACScalibur system (BD Biosciences GmbH, 
Schwechat, Austria) and analyzed using BD CellQuest software. 
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Table 3. 1 FACS antibodies 
Tube Epitopes Conjugate 
   
A Mouse IgM 
Mouse IgG 
Mouse IgG 2b 
Muse IgG2a 
FITC 
PE 
Percp 
APC 
 
B CD14 CD86 
CD 209 
CD83 
 
FITC 
PE 
Percp 
APC 
C 
 
CD 80 
CD 54 
HLADR 
 
FITC 
PE 
APC 
 
 
D 
CD 11c 
Mouse IgG1 
PE 
APC 
 
 
3.3.2 Cytokine detection by C ytometric bead array (CBA)  
 
BD CBA Flex Set bead-based immunoassay was used for measurement of cytokines by 
BD FACS calibur. The data generated by BD CBA are actually comparable to ELISA 
based assays, but in a "multiplexed" or simultaneous fashion (Figure 3.2). 
CBA data were analyzed using FCAP Array software 
 
Figure 3. 2 Cytometirc bead array 
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3.4 Statistical Analyses: 
 
Two way ANOVA with experiments assigned as blocked was applied to reveal significant 
differences LGG, L.delbrueckii, positive control (LPS), and negative control relative to 
capacity to induce co-stimulatory molecules expression and extra cellular cytokine 
production with two concentrations in 3 independent experiments. Bonferoni criterion was 
then used to compare the effect of each strain and the ratios with the two control groups. 
All analyses were performed using STATA (9.0) and the graphs were drawn by SPSS 16. 
Statistical significance was considered if p< 0.05. 
3.5 Gene expression analysis using real time Polymerase Chain Reaction (PCR) 
 
For this part of our study the same strains were co-cultred with DCs  at ratio of 10:1 
(CFU:DC) and  i ncubated for 12 hour s. The cells were collected in RNAlater (Ambion, 
Applied biosystem, USA) and stored in the freezer for further experiments. 
All end point PCRs for this study were performed by genXpress (Life Science) and the 
RT-PCRs by Applied Biosystems (ABI) StepOnePlus Instrument with 96 wells. 
3.5.1 mRNA extraction, Reverstranscription & amplification using Syber 
green 
 
Extraction of total mRNA was performed by RNeasy Mini Kit from Qiagen (Hilden, 
Germany) according to the instruction (appendix II). 
 Reverse transcription was followed  by 8 μl of mRNA template with the Phusion RT-PCR 
Kit from Finnzymes (Epoo, Finland) using Oligo(dT) primer, which consist of only 
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Thymine and bind to the polyA-tail of the mRNA. All the further steps were done 
according to the manual (apendixIII).  
For the RT PCRs, the following optimized reaction set up was applied:   
10μl of total reaction volume was prepared consisting: 
• 5 μl MasterMix: SensiMix SYBR Kit from genXpress (Wiener Neudorf, Austria) 
•  1 μl Primer, the concentration for each primer was considered separately according 
to the information provided and our inter lab experiments for each primer. All the 
primers were purchased from  biomers (genXpress,Wiener Neudorf, Austria  
• 3 μl nuclease free water 
• 1 μl  complementary DNA (cDNA) 
The Magnesiumchloride (MgCl2) concentration for all assays was 3mM. The SensiMix 
already contains the Sybr Green dye for the real-time analysis. 
The temperature conditions applied for this part is shown in table 3.2 a nd the primers 
which were purchased from biomers are listed in table 3.3, Further details appendix (IV) : 
Table 3. 2 Temperature setting for RT-PCR 
 
Step Annealing Temperature Time 
Hot Start for the Activation of 
the Polymerase 95°C 10 minutes 
Denaturation 95°C 30 seconds 
Annealing 57°C-60°C 40 seconds 
Elongation 72°C 30 seconds 
 Melt Curve  
40  
cycles 
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Table 3. 3 Primers sequences  
 
Primer Sequence5´-3´ 
Annealing 
temperature 
Concentration 
TNFα 
Forward:AAGAGGGAGAGAAGCAACTACAGA 
Reverse:GGTGGAGCCGTGGGTCAG 
60°C 0.25pmol/μl 
TLR4 
AAGCCGAAAGGTGATTGTTG 
CTGAGCAGGGTCTTCTCCAC 
52°C 0.24pmol/μl 
IKB 
Forward:GCTGTGATCACCACATTACCGTC 
Reverse: GAGTACATTTGCGCGTTCACG 
56°C 0.25pmol/μl 
P38 
Forward: ACTCAGATGCCGAAGATGAAC 
Reverse: GTGCTCAGGACTCCATCTCT 
51°C 2,5pmol/μl 
GAPDH  
Forward:CGACCACTTTGTCAAGCTCA 
Reverse:AGGGGAGATTCAGTGTGGTG 
58°C 0.5pmol/μl 
 
3.5.1 miRNA  Quantitation by RT-PCR  using TaqMan assay  
 
After removal of RNAlater and lysing the cells by 300-600µl Lysis Binding Solution, total 
miRNA was isolated by mirVanaTM miRNA Isolation Kit (Ambion,USA) (appendix V).  It 
has to be mentioned that mirVana isolation kit is designed for specifically purification of 
miRNA and by immobilization of large RNAs on the fibre filter with low ethanol 
concentration small-RNA enriched sample can be perfectly eluted.  
Afterwards, TaqMan MicroRNA assay(Applied biosystem, California) was applied for 
reverse transcription and RT-PCR amplification of selected miRNAs from the purified 
miRNA template  according to the protocol.  For this experiment TaqMan® Universal 
PCR Master Mix 2✕, No AmpErase® UNG was used. This kit includes the primers for 
the target miRNAs and U66 was used as endogenous control (appendix VI) 
48 
 
3.6 Gene expression Analysis 
 
Real time PCR data were analyzed with the StepOne software belonging to the StepOne 
real time PCR Life Technologies (Carlsbad, California). Gene expression data were 
normalized to the expression of the housekeeping gene Glycerinaldehyde-3-phosphate 
Dehydrogenase (GAPDH) & miRs U66.  Mean ± standard deviation (SD) of independent 
experiments performed in triplicate is demonstrated in figures.  One sample t- test and two 
sample t te st were applied to reveal significant differences of treatments relative to 
capacity to regulate gene expressions in three independent experiments at various time 
points. Statistical analysis were performed using OriginPro 8G ( OriginLab,Northampton, 
USA). The figures have been also made by OriginPro 8G. Results were considered 
significant if p<0.05.  
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3.6 Table of Variables 
No variable Type of 
variable quantitative qualitative Scientific definition 
Method of 
measurement scale 
  
in
de
pe
nd
en
t 
de
pe
nd
en
t 
co
nt
in
uo
us
 
N
on
 c
on
tin
uo
us
 
no
m
in
al
 
or
di
na
l 
   
1 
Lactobacillus 
Rhamnosus 
(LGG) 
 
*    
  *   A strain of lactic acid 
bacteria used as natural 
preservative in dairy 
product  
Counting 
colonies on 
MRS  culture 
Colony 
forming 
Unit 
(CFU) 
2 
Lactobacillus 
Delbrueckii 
(l. 
delbrueckii) 
 
*    
  *   A gram positive, 
facultative anaerobic, 
non motile and non spore 
forming, rod shaped  
Probiotic and a members 
of industrially important 
lactic acid bacteria 
Counting 
colonies on 
MRS  culture 
CFU 
3 LPS  *    
  *  Lipopolysacharide  a 
major cell wall 
constituents of gram 
negative bacteria 
weighting μg 
4 IL-1β   * *  
  Maturation factor for DC 
and an important 
mediator of the 
inflammatory responses 
Flow 
cytometry 
Pg/ml 
5 IL-10   * *  
  Anti-inflammatory 
cytokine with regulatory 
role on DC maturation 
Flow 
cytometry 
Pg/ml 
6 IL-12 
 
 * *  
  Inflammatory cytokine 
produced by DC , initiate 
and regulate cellular 
immune responses 
notably by inducing T 
and NK cells to produce 
IFN-  
Flow 
cytometry 
Pg/ml 
7 TNF-α  * *  
  Inflammatory cytokine 
involved in regulation of 
immune cells 
Flow 
cytometry 
Pg/ml 
 
8 IFN-ɣ     
  Type II interferon, 
polarizes immature DCs 
into Th1 cell–promoting 
effector DCs 
Flow 
cytometry 
Pg/ml 
 
8 CD 86  * *  
  Co-stimulatory  molecule 
on DC  involves in T cell 
activation 
Flow 
cytometry MFI 
9 CD 83  * *    Typical marker of fully mature dendritic cell 
Flow 
cytometry 
MFI 
10 CD 80  * *  
  Co-stimulatory  molecule 
on DC  involves in T cell 
activation 
Flow 
cytometry      MFI 
50 
 
 
 
  
12 CD 54  * *  
  Trans membrane protein, 
phenotypic marker of DC 
and indicator of DC 
activation state 
Flow 
cytometry 
MFI 
13 CD 14  * *  
  Surface antigen that 
regulate dendritic cell 
response and lifecycle 
after exposure to LPS  
Flow 
cytometry 
MFI 
14 CD 11c  * *  
  a type I transmembrane 
protein found at high 
levels on most human 
DC 
Flow 
cytometry 
 
15 mRNA  TNF-α  * *  
  
inflammatory cytokine 
RT-PCR 
2^-ddct 
16 mRNA TLR4   * *    LPS specific receptor for cell signaling 
RT-PCR 
2^-ddct 
17 mRNA P38  * *    Mitogen-activated protein  kinase 
RT-PCR 
2^-ddct 
18 mRNA Iκb  * *    inhibitor of nuclear factor kappa b 
RT-PCR 
2^-ddct 
19 miR7i  * *    microRNA targeting TLR 
RT-PCR 
2^-ddct 
20 miR146a  * *      2^-ddct 
21 miR155  * *     RT-PCR 2^-ddct 
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4. Results  
4.1 Expression of co-stimulatory molecules 
4.1.1 CD14 
 
 Expression of Cd14 which is a marker of monocytes and get reduced during 
differentiation of monocytes to dendritic cells remains at low levels in all samples.  LPS 
didn’t have notable stimulating effect in regulation of CD 14 (9.3± 2.0) in differentiated 
monocytes. Neither the Statistical difference between groups after adjustment for dilution 
nor the differences between concentrations in each group reached statistical significance 
(Figure 4.1.1).  
 
Figure 4.1.1 Expression of CD14  by DCs treated with Lactobacillus Rhamnosus GG (gg), 
Lactobacillus Delbrueckii (del), LPS (pc)  and no stimulants (nc) for 24 hours with 
bacteria:DC ratio of   10:1 (code1) and 100:1(code 2) .  Data are shown as means (± SD) 
and are representative of 3 independent experiments. 
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41.2 CD 11c 
 
Remarkable expression of CD11c, a well known marker of APCs was observed in all 
cultures. L.delbrueckii (10:1) increased expression of CD11c 5.3 fold comparing to none 
treated DCs. While increasing concentration of L.delbrueckii (100:1) doesn’t lead to higher 
levels of CD11c and the observed up regulating effect remained only 2.8 times more than 
non- treated cells.  
Moreover, treatment of DCs with LGG changed expression of CD11c 0.2 fold respecting 
to negative control and this effect is increased to 2.4 f old by 10 time increasing the 
concentration of LGG. 
Unlike probiotics LPS shows little effect on expression of this trans-membrane protein 
(68.4± 13.3 MFI vs. 71.1±30.5 MFI), (figure4.1.2) 
 
Figure 4.1.2 Expression of CD11c  by DCs treated with Lactobacillus Rhamnosus GG (gg), 
Lactobacillus Delbrueckii (del), LPS (pc)  and no stimulants (nc) for 24 hours with bacteria:DC 
ratio of   10:1 (code1) and 100:1(code 2) .  Data are shown as means (± SD) and are 
representative of 3 independent experiments 
  
53 
 
4.1.3 CD 86 
 
CD 86, maturation marker of DCs was significantly up-regulated among cultures after 
adjustment for concentrations (P<0.05). However, LGG seemed to be a stronger inducer of 
CD 86 than L.delbrueckii (104.1 ±107.9 MFI vs. 92.2± 77.2 MFI). Though comparing to 
negative control, up r egulation of CD 86 onl y achieved statistical significance by LGG 
(about 7.3 fold, p≤ 0.05). LPS was shown to have higher (192.6± 58.9 MFI) up regulating 
effect than probiotics with regard to this co-stimulatory molecule. 
Increasing concentration of probiotics didn’t lead to higher expression of CD86 in neither 
of groups (figure 4.1.3) 
 
 
Figure 4.1.3 Expression of CD86  by DCs treated with Lactobacillus Rhamnosus GG (gg), 
Lactobacillus Delbrueckii (del), LPS (pc)  and no stimulants (nc) for 24 hours with bacteria:DC 
ratio of   10:1 (code1) and 100:1(code 2) .  Data are shown as means (± SD) and are 
representative of 3 independent experiments 
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4.1.4  CD 83 
 
CD 83, is expressed 2.3 MFI, 1.9 MFI and 2.1 MFI more comparing to negative control by 
LPS, LGG and L.delbrueckii respectively. However, these differences do not reach 
statistical significance after adjustment for concentrations. Indeed higher concentration of 
probiotics didn’t cause a significant up regulation in CD 83 expression in neither of groups 
(Figure 4.1.4). 
 
 
Figure 4.1.4  Expression of CD83  by DCs treated with Lactobacillus Rhamnosus GG (gg), 
Lactobacillus Delbrueckii (del), LPS (pc)  and no stimulants (nc) for 24 hours with bacteria:DC 
ratio of   10:1 (code1) and 100:1(code 2) .  Data are shown as means (± SD) and are 
representative of 3 independent experiments 
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4.1.5 CD 80 
 
LGG up regulated CD80 to 21.2±2 MFI and 16.4±7.4 MFI at 10:1 and 100:1 
concentrations respectively. Whereas, L.delbrueckii didn’t seem to be much effective (11.1 
±4.5 MFI and 15.1±5 MFI) in induction of CD 80 c omparing to the non-treated DCs 
(11.6± 1.9 MFI). Although, LPS led to higher expression of CD80 than probiotics, neither 
the difference among cultures after adjustment for concentration nor within each group was 
found to be significant, (Figure 4.1.5) 
 
Figure 4.1.5 Expression of CD80  by DCs treated with Lactobacillus Rhamnosus GG (gg), 
Lactobacillus Delbrueckii (del), LPS (pc)  and no stimulants (nc) for 24 hours with bacteria:DC 
ratio of   10:1 (code1) and 100:1(code 2) .  Data are shown as means (± SD) and are 
representative of 3 independent experiments 
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4.1.6 CD 209 
 
 The expression of CD 209, the important receptor for endocytosis and DCs life cycle was 
significantly different among groups after adjustment for concentrations (p= 0.003). CD 
209 was significantly down regulated in LGG (100:1, p= 004) and L.delbrueckii (10:1, p= 
0.006; 100:1 p= 0.002) treated cultures. Evidently, L.delbrueckii (10:1) was about 3.6 
times more efficient in negative stimulation of CD 209 comparing to LGG(10:1). The 
negative stimulation was rather equally increased 27% by L.delbrueckii (124.7±34.0 MFI 
vs. 91.4± 24.0 MFI) and 28% by LGG (241.1±71.2 MFI vs. 173.3± 51.0 MFI) when their 
concentration was 10 times increased (Figure 4.1.6).   
 
Figure 4.1.6 Expression of CD209  by DCs treated with Lactobacillus Rhamnosus GG (gg), 
Lactobacillus Delbrueckii (del), LPS (pc)  and no stimulants (nc) for 24 hours with bacteria:DC 
ratio of   10:1 (code1) and 100:1(code 2) .  Data are shown as means (± SD) and are 
representative of 3 independent experiments 
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4.1.7 CD 54 
 
Expression of CD 54 was increased 73% (833.3± 154.3 MFI) by LGG (10: 1) and 12% 
(539.2± 284.5 M FI) by L.delbrueckii (10:1) comparing to non treated DC (479.7±399.5 
MFI). Surprisingly, 10 t imes increasing concentration of LGG and L.delbrueckii reduced 
expression of CD54, to  5 % (452.8± 267.7 MFI) and 26% (353.0±202.0 MFI) respectively 
comparing to negative control.  
Neither the difference among groups after adjustment for concentrations nor difference in 
concentrations within each group achieved statistical significance (Figure 4.1.7). 
 
Figure 4.1.7 Expression of CD14  by DCs treated with Lactobacillus Rhamnosus GG (gg), 
Lactobacillus Delbrueckii (del), LPS (pc)  and no stimulants (nc) for 24 hours with bacteria:DC 
ratio of   10:1 (code1) and 100:1(code 2) .  Data are shown as means (± SD) and are 
representative of 3 independent experiments 
 
 
58 
 
4.2 Cytokine levels 
4.2.1 IL-1 β 
 
Expression of IL-1β, an inflammatory cytokine, was increased by L.delbrueckii (77.4±38.3 
pg/ml) and LGG (99.5±47.7 pg/ ml) comparing to negative control at low concentration 
(10:1).  M oreover, the expression of IL-β was increased 5 times, by LGG (413.1±263.9 
pg/ml) and 1.7 t imes (169.1±98.3 pg/ml), by L.delbrueckii when their concentration was 
10 times increased. Hence, the difference between groups after adjustment for 
concentrations was statistically significant (p= 0.009).  Also there was a difference 
between concentrations in each group, although the significance level was borderline (p= 
0.055), (Figure 4.2.1). 
 
Figure 4.2.1 Level of IL-1β  in DCs treated with Lactobacillus Rhamnosus GG (gg), Lactobacillus 
Delbrueckii (del), LPS (pc)  and no stimulants (nc) for 24 hours with bacteria:DC ratio of   10:1 
(code1) and 100:1(code 2) .  Data are shown as means (± SD) and are representative of 3 
independent experiments 
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4.2.2 TNF-α 
 
Both probiotics stimulate TNF-α secretion. Obviously L.delbrueckii had the most 
significant stimulatory effect in induction of TNF-α at t 10:1 ratio (26.5 fold,p= 0.006) and 
even higher at 100:1 ratio    (50.2 fold, p= 0.0002) comparing to negative control. 
LGG also increased TNF-α level 2.5 fold at 10: 1 ratio which was not statistical significant 
but ten times increasing the concentration of LGG led to significantly higher (21.6 fold) 
expression of TNF-α comparing to negative control (p= 0.05). 
Accordingly, the difference between groups after adjustment for concentrations was 
statistically significant (p= 0.0001). Also there was a significant difference between 
concentrations in each group (p= 0.03), (Figure 4.2.2). 
 
 
Figure 4.2.2 Level of TNF-α  in DCs treated with Lactobacillus Rhamnosus GG (gg), Lactobacillus 
Delbrueckii (del), LPS (pc)  and no stimulants (nc) for 24 hours with bacteria:DC ratio of   10:1 
(code1) and 100:1(code 2) .  Data are shown as means (± SD) and are representative of 3 
independent experiments 
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4.2.3 IL-10 
 
 Expression of IL-10, an anti-inflammatory cytokine was increased 13.9 fold (134.4 pg/ml) 
by LGG (p=0.02) and 17.4 fold (170.1pg/ml) by L.delbrueckii (p=0.002) at 10: 1 ratio.  
Moreover, IL-10 level was noticeably raised when the concentration of probiotics was10 
times increased. Actually at 100:1 ratio IL-10 level was increased 38.6 fold (391.3 pg/ml) 
by   LGG (p=0.0006) and 21.7 fold (215.6 pg/ml) by L.delbrueckii (p= 0.005).   
 A significant difference was observed between groups in increasing IL-10 level after 
adjustment for concentrations (p= 0.01).However, the difference between concentrations 
in each group wasn’t found to be significant, ((Figure 4.2.3). 
 
 
Figure 4.2.3 Level of IL-10  in DCs treated with Lactobacillus Rhamnosus GG (gg), Lactobacillus 
Delbrueckii (del), LPS (pc)  and no stimulants (nc) for 24 hours with bacteria:DC ratio of   10:1 
(code1) and 100:1(code 2) .  Data are shown as means (± SD) and are representative of 3 
independent experiments 
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4.2.4  IL-12 
 
Expression of IL-12, the pro inflammatory cytokine was reduced (0.1 pg/ml) by LGG at 
low ratio (10:1) where as there was a significant increase in IL-12 level at cultures treated 
with higher ratio of LGG (1.7 pg/ml, p =0.01).  In L.delbrueckii- treated DCs, there was a 
minor increase (0.4 pg/ml) in IL-12 level at low ratio but there was a significant rise (1.6 
pg/ml, p=0.01) in DCs treated with higher ratio of L.delbrueckii.  So IL-12 level was only 
significantly increased at high ratio of probiotics to DCs (100:1). Moreover,   there was a 
significant difference among groups in increasing IL-12 level after adjustment for 
concentrations (p= 0.006). Also, the difference between concentrations within each group 
achieved statistical significance, (p=0.01), ((Figure 4.2.4). 
 
 
Figure 4.2.4 Level of IL-12  in DCs treated with Lactobacillus Rhamnosus GG (gg), Lactobacillus 
Delbrueckii (del), LPS (pc)  and no stimulants (nc) for 24 hours with bacteria:DC ratio of   10:1 
(code1) and 100:1(code 2) .  Data are shown as means (± SD) and are representative of 3 
independent experiments 
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4.2.5  INF-γ 
 
Level of INF-γ was increased l.6 pg/ml in LGG (10:1) treated DCs and 1.3pg/ml in 
L.delbrueckii (10:1) treated DCs.  Ho wever, at ratio of 100:1 these levels were 
significantly increased to 9.2pg/ml (p= 0.005) and 5.8pg/ml (p= 0.01) by LGG and 
L.delbrueckii respectively. Accordingly after adjustment for concentrations there was a 
significant difference in INF-γ level between groups (p= 0.002) and between 
concentrations in each group (p= 0.003), (Figure 4.2.5).   
 
Figure4.2.4 Level of INF-ɣ   in DCs treated with Lactobacillus Rhamnosus GG (gg), Lactobacillus 
Delbrueckii (del), LPS (pc)  and no stimulants (nc) for 24 hours with bacteria:DC ratio of   10:1 
(code1) and 100:1(code 2) .  Data are shown as means (± SD) and are representative of 3 
independent experiments 
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4.3 Gene expression experiments 
4.3.1 TLR4 mRNA 
 
Gene expression of TLR4 was shown to be down regulated by LGG (0.86±0.32,p=0.5)   
and more strongly by L.delbrueckii (0.52±0.39, p=0. 2) in the same direction that it was 
influenced by LPS (0.71±0.04,p=0.005) after 12 hours (figure4.3.1).  
 
 
Figure 4.3.1 Expression of TLR4 mRNA in DCs treated with Lactobacillus Rhamnosus GG (gg), 
Lactobacillus Delbrueckii (del) and LPS (pc) for 12 hours with bacteria:DC ratio of   10:1  
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4.3.2 P38 mRNA 
 
 Expression of P38 was down regulated by both strains as well as by LPS. However, only 
LGG’s down regulatory effect on p38 ( 0.47±0.1, p=0.01) was shown to be statically 
significant (Figure4.3.2).  
 
Figure 4.3.2 Expression of p38 mRNA in DCs treated with Lactobacillus Rhamnosus GG (gg), 
Lactobacillus Delbrueckii (del) and LPS (pc) for 12 hours with bacteria:DC ratio of   10:1 
  
65 
 
4.3.3  IKB mRNA 
 
 At our measuring time point (12 hours after incubation) L.delbrueckii seemed to have  
significantly influenced the signaling pathway through inhibition of Ikb expression 
(0.37±0.2, p=0.03), while LGG showed quite no effect on IKb expression ( Figure 4.3.3). 
 
Figure 4.3.3 Expression of IκB mRNA in DCs treated with Lactobacillus Rhamnosus GG (gg), 
Lactobacillus Delbrueckii (del) and LPS (pc) for 12 hours with bacteria:DC ratio of   10:1 
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4.3.4 TNF-α  mRNA  
 
Only LPS led to a significant up- regulation in TNF-α gene expression (2.28±0.3,p=0.02)  
after 12 hour s. Neither inactivated form of LGG (1.12±0.3, p=0.6) nor L.delbrueckii 
(0,9±0.4,p=0.7)  affect TNF-α  mRNA expression in our experimental setting ( bacteria: 
DC. 10: 1, after 12 hours) Figure 4.3.4). 
 
 
Figure 4.3.4 Expression of TNF-α mRNA in DCs treated with Lactobacillus Rhamnosus GG (gg), 
Lactobacillus Delbrueckii (del) and LPS (pc) for 12 hours with bacteria:DC ratio of   10:1 
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4.3.5 miRNA 146a 
 
Expression of miRNA146a was significantly down-regulated by LGG (0.6±0.01, p=0.02) 
where as LPS (1.21±0.3, p=0.3) and L.delbrueckii (1.29±0.2, p=0.2) were not particularly 
changing the expression level of this miRNA (Figure4.3.6) 
 
Figure 4.3.6 Expression of miRNA146a  in DCs treated with Lactobacillus Rhamnosus GG (gg), 
Lactobacillus Delbrueckii (del) and LPS (pc) for 12 hours with bacteria:DC ratio of   10:1 
  
68 
 
4.3.6 miR155 
 
Expression of miR155 showed to be mostly influenced by LPS (1.57±0.1,p=0.02) and 
LGG (1.53±0.4, p=0.1). In DCS treated with L.delbrueckii no recognizable effect was 
found on miR155 expression (1.18±0.2,p=0.3), (figure 4.3.7 ). 
 
Figure 4.3.4 Expression of miRNA 155 in DCs treated with Lactobacillus Rhamnosus GG (gg), 
Lactobacillus Delbrueckii (del) and LPS (pc) for 12 hours with bacteria:DC ratio of   10:1 
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4. Discussion 
Immuno-modulatory effect of probiotic bacteria including lactobacilli is widely 
emphasized in literature (Borchers, et al., 2009; Corthesy, et al., 2007; Elmadfa, et al., 
2010). However, the absence of comprehensive mechanistic data makes the interpretation 
of the vast array of available findings rather conflicting. It remains unclear to what extent, 
via which mechanisms or which components of probiotics (the whole viable bacteria, cell 
wall component, soluble compounds, metabolites or heat resistant components) are 
responsible for the immune modifications which favor anti-inflammatory or regulatory 
responses.  Unlike most studies that have investigated only the effect of viable probiotics 
or cell wall extracts this study also examined whether nonviable LGG and L.delbrueckii 
can provoke immune modulatory effect by targeting DCs that are the key cells responsible 
for orchestrating further immune responses. 
Our results clearly demonstrated that non vi able LGG had considerable capacity to up 
regulate expression of co-stimulatory molecule CD86 (B7.2), the hallmark of dendritic cell 
activation and maturation (Dilioglou, et al., 2003; Nguyen, et al., 2002),  along with CD80 
(B7.1) and CD83. So we can say that LGG is able to provide the necessary stimuli for 
priming T cells. On the other hand, CD86 and CD83 were noticeably up regulated by 
L.delbrueckii while no effect was observed in induction of CD80.   
The dose of lactobacilli didn’t however influence the expression of these co-stimulatory 
molecules. Based on the fact that CD80 favors the activation of TH1 lymphocytes, CD86 
favors priming of TH2 cells and the relative amounts of CD86 and CD80 on DC influence 
the type of T cell response, it is therefore thought that LGG and L.delbrueckii stimulate 
different immune responses (Drakes, et al., 2004; Zheng, et al., 2004). This divergence in 
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stimulatory effect of LGG and L.delbrueckii was not confined to CD80, CD86 and CD83.  
Actually, L.delbrueckii was also able to up-regulate CD11c, a marker of myeloid DC, more 
than LGG especially at lower ratios (10:1) whereas CD54 was up-regulated more by LGG. 
Increasing the ratio of probiotics diminished the stimulatory effect of LGG and 
L.delbrueckii on CD54 expression. 
On the other hand,  expression of dendritic cell-specific ICAM-3 grabbing non-integrin (DC-
SIGN; CD209) was reduced after 24 hours by L.delbrueckii and LGG in dose dependent 
manner.  It is known that binding of pathogens to DC-SIGN leads to Ag processing and 
DC–T Cell clustering and DC-induced T cell proliferation (Geijtenbeek, et al., 2002). 
Subversion of this process can induce infection by some pathogens. In addition some 
viruses are reported to use DC-SIGN to establish infection in the host (Rappocciolo, et al., 
2006). This result is not persuasive enough to describe inactivated LGG and L.delbrueckii 
as stimulants which weaken T cell responses in pathogenic conditions. This study had no 
inflammatory stimuli whose existence and binding to CD209 in the cultures may have 
possibly changed the above findings. 
Additionally, unique cytokine production profile of MODCs after treatment with LGG and 
L.delbrueckii was analyzed. The results indicated both strains werre not only able to 
maturate DCs but also to yield considerable cytokine production in their non viable form. 
LGG was found to augment the secretion of immunosuppressive cytokine IL-10 which 
inhibits activation and function of effector T cells (Pena & Versalovic, 2003). This finding 
is in accordance with in vivo results demonstrating generation of IL-10 in atopic children 
after oral administration of LGG. Negative effect of IL-10 in TH2 cell differentiation and 
expansion and the  shift from TH2 response toward long lasting TH1 response lead to the 
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idea of using probiotics, such as LGG, as a novel therapeutic strategy for treatment of 
allergic disease (Kalliomaki, et al., 2001; Vissers, et al., 2011). Production of IL-10 by 
LGG stimulated DCs might also lead to differentiation and function of T regulatory cell 
(Treg) subsets (Calcinaro, et al., 2005; Yu, et al., 2010).  Nevertheless secretion of IL-1β 
and, to a lesser extent TNF-α, was also found to increase after incubation of DCs with 
LGG especially at ratio of 100:1 of bacteria to DC.  IL-12 as well as INF-γ also increased 
when DCs were stimulated with higher concentration of LGG. The moderate secretion of 
pro-inflammatory cytokines by probiotic bacteria stimulated MODCs has been explained 
by induction of low grade inflammation, maintenance of the balance between TH1 and 
TH2 responses and maintenance of Treg cells  that might in turn protect allergy prone 
people from development of allergy (Fink, 2010; Marschan, et al., 2008).  Also IL-12 is 
known to limit establishment and maintenance of TH2 type responses mainly by enhancing 
INF-γ production. This can explain why the presence of lactic acid bacteria in in-vitro 
models is associated with reduction of TH2 cytokine release (Meijerink & Wells, 2010). 
 This study found that DCs treated with L.delbrueckii secreted more INF-γ, IL-12, IL-10 
and IL1-β than non treated DCs.  At probiotic:DC ratio of 10:1, L.delbrueckii 
demonstrated the same capacity as LGG for producing all cytokines except TNF-α. 
L.delbrueckii led to significantly higher expression of TNF-α than LGG at both measured 
concentrations. The orientation of the immune response by L.delbrueckii may differ from 
LGG especially at higher concentrations, because LGG led to higher production of IL-10, 
IL1-β and INF-γ where as L.delbrueckii markedly increased TNF-α after 24 hours 
incubation. Probiotic bacteria which induce a pattern of maturation of DC characterized by 
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release of TNF-α and IL-12 with increased levels of IL-10 are said to inhibit generation of 
pro-inflammatory TH1 cells. 
Administration of heat killed of other strains of Lactobacilli, such as L.casei shirota, had 
also down regulated existing TH2 allergic response and pulmonary inflammatory response 
in subcutaneous and air way allergy challenges (Lim, et al., 2009). Different species of UV 
exposed lactobacilli have also yielded identical results in producing T reg cells, indicating 
that regulatory DC priming does not depend on viability of the bacteria. It is supposed that 
probiotics have heat–stable anti-proliferative components which are located in the 
cytoplasm and not in the cell walls and are responsible for immuno-suppressive effects 
(Pessi, et al., 1999). 
In the above findings, the strain specific capability of lactobacilli to up-regulate surface 
markers didn’t correlate with the cytokine induction profile. 
Probiotics not only interfere with generation of mature DCs but also influence the survival 
of DCs. Future studies should examine the duration that probiotics can stay within DCs by 
monitoring immune responses and how they affect DCs viability and whether or not the 
remains of probiotic-killed DCs can be processed by viable DCs in the environment. 
Additionally, we know that sensing of bacterial products by the immune system is 
mediated by Toll-like receptors. TLR4, the first of the TLRs described, has been the focus 
of particular interest since its recognition as the receptor for LPS and is widely studied on 
both enterocytes and immune cells. In this study we have reported that the expression of 
TL4 is influenced by LGG and L.delbrueckii as it is influenced by LPS. Although LPS is 
known to have positive stimulatory effect on T LR4 we have to consider that this 
73 
 
stimulation follows a time kitenetic pattern and the expression level do not remains 
constant at transcriptional level for a long time during exposure to LPS or other ligands. 
 Several recent studies have reported that the signaling pattern of gram negative bacteria 
slightly differs from that of gram positive bacteria, and most cases Gram-positive 
probiotics bacteria are shown to induce TLR2 expression via interactions with lipoteichoic 
acids but not TLR4 expression.  H owever,a recent study by Votan et al (2007) 
demonstrated that Gram-positive L.crispatus increases TLR2 and reduces TLR4 mRNA in 
clonic mucosa of mice.  Also Lactobacillus casei CRL 431 administration to healthy mice 
increased the expression of TLR2, TLR4 and TLR9 and improved the production and 
secretion of TNFα, IFNγ and IL-10 in the inductor sites of the gut immune response 
Peyer's patches. Although probiotics and pathogenic bacteria may share TLR signaling, 
their downstream substrates and outcomes could be different. For example, both 
L.rhamnosous GG and Streptococcus pyogenes enhance TLR2 expression and the 
subsequent NFkB activation depends on this expression. However, in addition to enhanced 
TLR2 gene expression s.pyogenes also up-regulates TLR3 and TLR7 expression resulting 
different response ( Miettinen 2008). In human cells, L.rhamnosus GG upregulates TLR2 
and TLR9 transcription levels as well as protein levels of TLR2 and TLR5 (Vizoso et al., 
2009). So we have to notice that there is a cross talk between different TLRs which can 
indirectly influence activation of one another. In this study the observed down regulatory 
effect of LGG and L.delbrueckii on TL4 might be the result of an indirect effect of ligation 
of particles of these strains to other TLRs.  
Furthermore, activation of TLR4 signal is related to induction of various signaling 
pathways including NFκB and P38 MAPK, and release of inflammatory cytokines. We 
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have observed that both strains of lactobacilli were able to influence p38 a nd IKB 
expression. However, LGG’s effect was more significant on dow n regulating p38 
expression and L.delbrueckii induced significant inhibitory response in IKB expression. 
Infact optimal’ NF-κB activity plays a significant role in maintaining normal immune 
homeostasis. The inflammatory responses involve the inhibitor of kB (IkB)/nuclear factor 
(NF)kB complex. NFkB is usually bound in the cytoplasm to the inhibitory molecule IkB, 
but in response to certain stimuli, phosphorylation, ubiquitination, and proteolysis of IkB 
occur, resulting in NFkB nuclear translocation and proinflammatory mediation. Inhibititon 
of IkB degradation thereby prevents NFkB translocation. The observed down regulation in 
IKB mRNA expression might be the reason of high level of IKB at protein level at the 
measuring point which could have consequently inhibited NFKb response and ultimately 
inhibited the production of inflammatory cytokines. In other studies it has been shown that 
that live and UV-inactivated LGG mechanisms of action in down regulating inflammatory 
products in inflammatory induced conditions merge at the IkB and NFkB steps. Actually, 
some probiotics strains and even their cellular components such as L. casei are reported to 
activate both NF-kB and p38 M APK signaling pathways (kim 2005). In a human and 
murine inflammatory model, VSL#3 DNA inhibited IL-8 secretion, reduced p38 mitogen-
activated protein kinase activation, delayed nuclear factor kappaB activation, stabilized 
levels of IkappaB, and inhibited proteasome function . Similarly, S. boulardii prevented 
enterohemorrhagic Escherichia coli infection by interfering with the transduction pathways 
that control tight-junction structure as well as inhibiting NF-κB and MAPK signaling 
pathways leading to the production of IL-8. 
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The novel approach of our study was to look for the epigenetic mechanisms which 
probiotics might be involved. Though, we looked for the effect of our strains on expression 
of miRNAs which have been validated for DCs. Although it is concluded that miRNAs 
participate in the regulation of immune system there is still no published result with regard 
to the effect of probiotics on miRNA expression. We have observed for the first time that 
LGG significantly down- regulate miRNA146a, which is known to directly control TLR4 
and regulate the maturation process in dendritic cells .  However, LPS and L.delbrueckii 
showed a little up-regulatory effect on expression of this miRNA. Previous studies have 
shown that LPS- induced regulation of miRNA146a is cell-type-specific and it depends to 
the cell environment (Moschos, et al., 2007). Indeed it has been shown that only the 
ligands of TLRs that recognize bacterial constituents and reside on the cell surface are able 
to induce miR146 expression(K. D. Taganov, et al., 2007). Whereas the noteworthy 
finding of our study is that our tested strains have modified miR146 expression in spite of 
being autoclaved which their surface components have been defiantly denaturated.  
Until now we just know that aberrant miRNA146 expression is related to systemic 
autoimmune disorders and chronic inflammation. Thus determination whether probiotics 
as immune modulating agents can be used to modulate miRNA in vivo represents 
important further research task.   
Finally we have also found that miRNA 155 is considerably up-regulated in LPS and LGG 
treated DCs. In a recent study highly up-regulation of miR155 during dendritic cell 
maturation has been reported and it is shown that miR155 modulates TLR/IL-1 signaling 
pathway in activated monocyte derived dendritic cells. More importantly, it has been 
reported that the top ranked pathway whose genes are mostly up-regulated upon miR155 
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inhibition are the p38MAPK pathway (Ceppi, et al., 2009). This finding support our results 
that show significant down-regulation in p38 expression in LGG treated DCs that induce 
higher expression of miR155 at the same time. In fact, in resting DCs, low miR155 levels 
may enable the activation of p38 M APK pathway, while in activated DCs induction of 
miR155 and miR146 can lead to decreased p38 MAPK pathway and consequently, limit 
the over production of inflammatory cytokines. In addition to the regulatory role of 
miR155 in TLR4 signaling, it was recently shown that miR155 also regulates human 
dendritic cell function by modulating their pathogen binding ability, through down 
regulation of DC-SIGN, resulting in impaired recognition and binding of pathogens (R. T. 
Martinez-Nunez, et al., 2009). In accordance to this finding we have seen significant 
down-regulation of DC-SIGN in DCs treated with LGG and L.delbrueckii.  These findings 
provide genetic and epigenetic mechanistic explanations for the proposed anti-
inflammatory effect of LGG in inflammatory conditions such as inflammatory bowel 
disease. 
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5. Conclusion 
 
 
By combining the results of the current in-vitro study we can suggest that nonviable LGG 
and L.delbrueckii possess heat stable components that influence functional ability of DCs 
to generate specific immune responses depending on the level of co-stimulatory molecule 
expression and cytokine production profile.  
We have provided evidence for the first time that autoclaved probiotics are not only able to 
influence key immune signaling nodes at transcriptional level but also interact with 
miR146 and miR155. Thereby, target genes responsible for DCs maturation, pathogen 
binding capacity such as DC-SIGN, and cytokine signaling pathways including TLR4 and 
p38MAPK at post- transcriptional level.  
These effects in autoclaved probiotics strains are shown to be absolutely strain specific as 
in live strains. Therefore, lactobacilli viability may not be required for regulating DC 
priming and immuno-modulation.  
Additionally, dose-dependent responses of probiotics indicate involvement of different 
signaling pathways at higher doses. 
Continuation of studies using probiotics loaded DCs is a fertile field for investigating the 
mechanism of action of probiotics which is hoped to lead us to a new paradigm for 
development of desirable immune responses. 
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6. Limitation 
 
Due to the nature of in vitro experimental setting it won’t be precise to extrapolate the 
results of in vitro immuno-modulatory properties of probiotics to in vivo conditions. 
However, some researchers have shown that in vitro immune profiling of strains can be 
predictive of their in vivo protective effect in mice models. So the first and most important 
limiting factor is the method of DCs differentiation in vitro by GMCSF and IL-4. No 
doubt, DCs development in vivo differs in cytokine dependency, and the micro 
environment at the differentiating stage has a great impact on fine complex properties of 
the differentiated cell. 
The second prominent fact is that we have looked for the effect of each strain individually 
to find their individual effects, while practically we are never exposed to a single strain and 
actually each single strain is going to induce a response which is indirectly influenced by a 
cross talk with immense variety of commensal strains.  
Third point is that all the biologic responses and events in signaling pathways specifically 
at transcriptional level follow a conscious time kinetic response that for better 
understanding of the effect of our stimulation it would have been better that we could have 
selected different time points. However, due to limitations in producing sufficient number 
of DCs for each experiment that was not feasible in this study. 
Forth, the high standard deviation in expression of some CD markers would have been 
narrowed in case of having the possibility to run more experiments. 
So it is believed that investigating the effect of probiotics on immune system, in viable or 
nonviable condition is worth to be done with a more systemic approach considering the 
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well explained network of responses which take place in conscious timing in a setting 
which resembles the in vivo condition as much as possible. 
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7. Summary 
 
Strain specific immunomodulatory effect of probiotics is among their key health benefit. It 
is believed that probiotics determine the fate of an immune response by targeting and 
polarizing dendritic cells. Therefore we studied the effects of a heat-inactivated form of 
Lacto bacillus rhamnosus GG (LGG) and Lactobacillus delbrueckii (L.delbrueckii) on 
maturation pattern and extracellular cytokine production profile of monocyte derived 
dendritic cells. Expression of specific maturation markers and induction of extracellular 
cytokines were detected by flow cytometry. Up regulation of CD86, CD80, and CD83 and 
down regulation of DCSIGN was observed after 24 hours co-incubation. In addition, LGG 
induced secretion of high levels IL-10, INF-γ and IL-1β whereas. L.delbrueckii seemed to 
be more potent in induction of TNF-α in a dose dependent manner. These results indicated 
that non-viable forms of both tested strains are able to induce divergent immune regulatory 
effects via the induction of phenotypic changes and cytokine production of dendritic cells.  
Moreover, as the immune response is initiated by recognition through toll like receptors 
and activation of network of downstream signaling pathways, we investigated the effect of 
autoclaved LGG and L.delbrueckii on expression of TLR4 and signaling factors such as 
P38MAPK and IκB at transcription level. Our findings demonstrated that even autoclaved 
probiotics strains can affect TLR4 expression in a down regulatory direction as LPS after 
12 hours. Indeed, LGG significantly down regulated expression of P38 while IκB 
expression was significantly reduced in L.delbrueckii- treated DCs. 
Finally, we found the tested strains could even influence immune response at post 
transcriptional level by modifying miRNAs expression. Based on our  findings LGG 
induced significant down regulatory effect on miRNA146a expression which is known as a 
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novel fine negative regulator of immune response that targets NFκB. On the other hand, 
miRNA 155 was up-regulated by LGG which is consistent with down-regulation of p38 
and DC-SIGN expression in LGG- treated dendritic cells. These findings provide genetic 
and epigenetic explanations for the responsible underlying mechanisms by which 
probiotics influence immune response by targeting dendritic cells. 
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Zusammenfassung 
Einer der wichtigsten gesundheitlichen Wirkungen von Probiotika sind stammspezifische 
immunmodulatorische Effekte. Man geht davon aus, dass Probiotika die Art der 
Immunantwort durch das Ansprechen und Polarisieren von de ndritischen Zellen 
regulieren. Daher untersuchten wir die Effekte von H itze-inaktivierten Lactobacillus 
rhamnosus GG (LGG) und Lactobacillus delbrueckii (del) auf die Reifung und das Profil 
der extrazellulären Zytokinproduktion von de ndritischen Zellen, die aus Monozyten 
gewonnen wurden. Die Expression verschiedener Reifungsmarker und die Induktion 
extrazellulärer Zytokine wurden mit Durchflusszytometrie gemessen. Nach 24 S tunden 
Ko-Inkubation wurden ein Anstieg von CD86, CD80 und CD83, sowie ein Absinken von 
DCSIGN beobachtet. Zusätzlich induzierte LGG die Sekretion von hoh en Levels IL-10, 
INF-γ und IL-1β, während L.del größeres Potenzial in der dosisabhängigen Induktion von 
TNF-α aufzeigte. Diese Resultate lassen vermuten, dass abgetotete Formen beider 
getesteten Stämme fähig sind, unterschiedliche immunregulatorische Effekte über die 
Induktion von phänotypischen Änderungen und die Zytokinproduktion von dendritischen 
Zellen hervorzurufen. 
Desweiteren untersuchten wir die Effekte von a utoklavierten LGG und del auf die 
Expression von T LR4 und Signaltransduktionsfaktoren wie z.B. P38MAPK und IκB, da 
die Immunantwort über toll-like Rezeptoren und die Aktivierung von Netzwerken der 
weiterführenden Signaltransduktion initiiert wird. Unsere Ergebnisse zeigten, dass auch 
autoklavierte, probiotische Stämme die TLRR4-Expression herabregulierend beeinflussen 
können wie LPS nach 12 Stunden. Die Expression von P38 wurde durch LGG signifikant 
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herabreguliert, während die IkappaB-Expression in del-behandelten DZs signifikant reduziert 
war. 
Außerdem stellten wir fest, dass die getesteten Stämme die Immunantwort sogar post-
transkriptional durch die Modifikation der miRNA-Expression beeinflussen konnten. 
Unsere Ergebnisse zeigten, dass LGG ein signifikantes Absinken der Expression der 
miRNA146a induziert, die bekanntermaßen die NFκB -vermittelte Immunantwort negativ 
reguliert. Andererseits wurde miRNA 155 dur ch LGG hinaufreguliert, was mit d em 
Absinken der p38 und  DC-SIGN-Expressionen in LGG-behandelten dendritischen Zellen 
einhergeht. Diese Ergebnisse bieten genetische und epigenetische Erklärungen für die 
verantwortlichen zugrundeliegenden Mechanismen, durch welche Probiotika die 
Immunantwort über DZs beeinflussen. 
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Protocols 
Appendix I Dynal® Monocyte Negative Isolation Kit  
http://tools.invitrogen.com/content/sfs/manuals/113.09_10%20Dynal_Monocyte_Negative_Isolation_Ki
t.pdf 
Dynabeads Washing Procedure 
1. Resuspend the Dynabeads in the vial to a homogenous suspension. 
2. Transfer the desired volume of Dynabeads to a tube. 
3. Add the same volume of Buffer 1, or at least 1 ml, and mix. 
4. Place the tube in a magnet for 3 min and discard the supernatant. 
5. Remove the tube from the magnet and resuspend the washed Dynabeads in the same 
volume 
of Buffer 1 as the initial volume of Dynabeads (step 2). 
Preparation of MNC from Buffy Coat to Obtain Low Platelet Numbers 
1. Dilute 10 - 18 ml buffy coat with Buffer 2 to a total volume of 35 ml at room 
temperature. 
2. Add the diluted buffy coat on top of 15 ml of Lymphoprep™. 
3. Centrifuge at 160 x g for 20 minutes at 20°C. Allow to decellerate without brakes. 
4. Remove 20 ml of supernatant to eliminate platelets. 
5. Centrifuge at 350 x g for 20 minutes at 20°C. Allow to decellerate without brakes. 
6. Recover MNC from the plasma/Lymphoprep interface and transfer the cells to a 50 ml 
tube. 
7. Wash MNC once with Buffer 1 by centrifugation at 400 x g for 8 minutes at 2-8°C. 
8. Wash MNC twice with Buffer 1 by centrifugation at 225 x g for 8 minutes at 2-8°C and 
resuspend the MNC at 1 x 108 MNC per ml in Buffer 1 (keep cold). 
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Isolation of Human Monocytes from MNC 
This protocol is based on 1 x 107 MNC. It can be scaled up from 1 x 107 - 5 x 108 cells  
1. Transfer 100 μl (1 x 107) MNC in cold Buffer 1 to a tube. 
2. Add 20 μl Blocking Reagent.  
3. Add 20 μl Antibody Mix. 
4. Mix well and incubate for 20 min at 2-8°C. 
5. Wash the cells by adding 2 ml Buffer 1. Mix well by tilting the tube several times and 
centrifuge at 300 x g for 8 min at 2-8°C. Discard the supernatant. 
6. Resuspend the cells in 900 μl Buffer 1.  
7. Add 100 μl pre-washed Depletion Dynabeads and mix well. 
8. Incubate for 15 min at 2-8°C with gentle tilting and rotation. 
9. Resuspend the bead-bound cells by gently pipetting 5 times using a pipette with a 
narrow 
tip opening (e.g. a 1000 μl pipette tip or a 5 ml serological pipette). 
10. Add 1 ml Buffer 1. 
11. Place the tube in the magnet for 2 min. 
12. Transfer the supernatant to a new tube. 
13. Repeat step 10-12. 
The supernatant contains the untouched human monocytes. 
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Appendix II   Protocol Purification of Total RNA from Animal Cells 
                                                   www.qiagen.com/hb/rneasymini 
Harvest cells according to step 1 
1. Cells grown in suspension (do not use more than 1 x 107 cells): Determine the number 
of cells. Pellet the appropriate number of cells by centrifuging for 5 min at 300 x g in a 
centrifuge tube (not supplied). Carefully remove all supernatant by aspiration. 
2. Disrupt the cells by adding Buffer RLT. For pelleted cells, loosen the cell pellet 
thoroughly by flicking the tube. Add the appropriate volume of Buffer RLT . Vortex or 
pipet to mix 
 
 
Number of pelleted cells                                                           Volume of Buffer  RLT (µl) 
<5 x 106                                                                                                                                                               350 
5 x 106   – 1 x 107                                                                                                                                          600 
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3. Homogenize the lysate for 30 s using a rotor–stator homogenizer.  
4. Add 1 volume of 70% ethanol to the homogenized lysate, and mix well bypipetting. Do 
not centrifuge. 
5. Transfer up to 700 μl of the sample, including any precipitate that may have formed, to 
an RNeasy spin column placed in a 2 ml collection tube (supplied). Closethe lid gently, 
and centrifuge for 15 s  at _8000 x  g (_10,000 rpm). Discard theflow-through. Reuse the 
collection tube in step 6.  
If the sample volume exceeds 700 μl, centrifuge successive aliquots in the same RNeasy 
spin column. Discard the flow-through after each centrifugation  
6. Add 700 μl Buffer RW1 to the RNeasy spin column. Close the lid gently, and centrifuge 
for 15 s at _8000 x g (_10,000 rpm) to wash the spin column membrane. Discard the flow-
through.  Reuse the collection tube in step 7. 
7. Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently, and centrifuge 
for 15 s at _8000 x g (_10,000 rpm) to wash the spin column membrane. Discard the flow-
through. Reuse the collection tube in step 8. 
8. Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently, and centrifuge 
for 2 min at _8000 x g (_10,000 rpm) to wash the spin column membrane. 
9. Optional: Place the RNeasy spin column in a new 2 ml collection tube (supplied),and 
discard the old collection tube with the flow-through. Close the lid gently, and centrifuge 
at full speed for 1 min. Perform this step to eliminate any possible carryover of Buffer 
RPE, or if residual 
flow-through remains on the outside of the RNeasy spin column after step 8. 
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10. Place the RNeasy spin column in a new 1.5 ml collection tube (supplied). Add 30–50 
μl RNase-free water directly to the spin column membrane. Close the lid gently, and 
centrifuge for 1 min at _8000 x g (_10,000 rpm) to elute the RNA. 
11. If the expected RNA yield is >30 μg, repeat step 10 using another 30–50 μl RNasefree 
water, or using the eluate from step 10 (if high RNA concentration is required). Reuse the 
collection tube from step 10. 
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Appendix III  Phusion RT-PCR Kit Finnzymes Protocol for cDNA synthesis 
                             www.finnzymes.fi/rt-pcr/Phusion_rt-pcr_kit.html 
1. Thaw template RNA, 10x RT buffer, Deoxynuclteotidtriphosphat (dNTPs) and primers. 
Mix the individual solutions to assure homogeneity and centrifuge briefly before pipetting. 
2. Combine the following components in reaction tubes: 
 Template RNA x μl (up to 1 μg) 10 mM dNTP mix 1 μl 
Oligo(dT) primer* 1 μl 
RNase-free H2O Add to 10 μl 
3. Incubate at 65°C for 5 minutes to predenature the RNA. 
4. Place the reaction tubes on ice and add to each tube  
10x RT buffer 2 μl 
RT enzyme mix 2 μl 
RNase-free H2O 6 μl 
5. Program a thermal cycler: 
Primer extension 25°C 10 min 
cDNA synthesis 40°C 30 min 
Reaction termination 85°C 5 min 
Cooling of the sample 4°C Hold 
 
6. Place the tubes in the cycler and start the program. 
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Appendix IV QuantiMir RT Kit Small RNA Quantitation System 
 
             www.genycell.es/images/productos/protocolos/sbra420a-1__43.pdf 
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Appendix V  mirVana™ miRNA Isolation Kit 
 
http://www.ambion.com/techlib/prot/fm_1560.pdf 
 
1. Add 1.25 volumes 100% ethanol, and mix thoroughly: Add 1.25 volumes of room 
temperature 100% ethanol to the aqueousphase (e.g. if 300 μL was recovered in step E.3, 
add 375 μL ethanol). 
2. Pass the lysate/ethanol mixture through a Filter Cartridge:  Pass the lysate/ethanol 
mixture through a Filter Cartridge 
a. For each sample, place a F ilter Cartridge into one of the Collection Tubes 
supplied. 
b. Pipet the lysate/ethanol mixture (from the previous step) onto the Filter 
Cartridge. Up to 700 μL can be applied to a Filter Cartridge at a time, for samples 
larger than this, apply the mixture in successive applications to the same filter. 
c. Centrifuge for ~15 sec to pass the mixture through the filter: Centrifuge at RCF 
10,000 x g (typically 10,000 rpm). Spinning harder than this may damage the 
filters. Alternatively, vacuum pressure may be used to pass samples through the 
filter. 
d. Discard the flow-through, and repeat until all of the lysate/ethanol mixture is 
through the filter. Reuse the Collection Tube for the washing steps. 
3. Apply 700 μL miRNA Wash Solution 1 (working solution mixed with ethanol) to the 
Filter Cartridge and centrifuge for ~5–10 sec or use a vacuum to pull the solution through 
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the filter. Discard the flow-through from the Collection Tube, and replace the Filter 
Cartridge into the same Collection Tube. 
4. Wash the filter twice with 500 μL Wash Solution 2/3:  
a. Apply 500 μL Wash Solution 2/3 (working solution mixed with ethanol) and 
draw it through the Filter Cartridge as in the previous step. 
b. Repeat with a second 500 μL aliquot of Wash Solution 2/3. 
c. After discarding the flow-through from the last wash, replace the Filter Cartridge 
in the same Collection Tube and spin the assembly for 1 min to remove residual 
fluid from the filter. 
5. Elute RNA with 100 μL95°C Elution Solution : Transfer the Filter Cartridge into a 
fresh Collection Tube (provided with the kit). Apply 100 μL of pre-heated (95°C) Elution 
Solutionto the center of the filter, and close the cap. Spin for ~20–30 sec at maximum 
speed to recover the RNA. Collect the eluate (which contains the RNA) and store it at –
20°C or below. 
F.II. Enrichment Procedure for Small RNAs 
This variation of a traditional glass-fiber filter RNA purification yields RNA that is 
significantly enriched for small RNAs. This enrichment is accomplished by first 
immobilizing large RNAs on the filter with a relatively low ethanol concentration and 
collecting the flow-through containingmostly small RNA species. More ethanol is then 
added to this flow-through, and the mixture is passed through a second glass filter where 
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the small RNAs are immobilized. This second filter is then washed a few times, and the 
small-RNA enriched sample is eluted. 
1. Add 1/3 volume 100% ethanol, and mix thoroughly: Add 1/3 volume of 100% 
ethanol to the aqueous phase recovered from the organic extraction (e.g. add 100 μL 100% 
ethanol to 300 μL aqueous phase). Mix thoroughly by vortexing or inverting the tube 
several times. 
2. Pass the sample through a Filter Cartridge, and collect the filtrate:  
a. For each sample, place a F ilter Cartridge into one of the Collection Tubes 
supplied. 
b. Pipet the lysate/ethanol mixture (from the previous step) onto the Filter 
Cartridge. Up to 700 μL can be applied to a Filter Cartridge at a time. For sample 
volumes greater than 700 μL, apply the mixture in successive applications to the 
same filter. 
c. Centrifuge for ~15 sec to pass the mixture through the filter. Centrifuge at RCF 
10,000 x g (typically 10,000 rpm). Spinning harder than this may damage the 
filters. Alternatively, vacuum pressure can be used to pull samples through the 
filter. d. Collect the filtrate. If the lysate/ethanol mixture is >700 μL, transfer the 
flow-through to a fresh tube, and repeat until all of the lysate/ethanol mixture is 
through the filter. Pool the collected filtrates if multiple passes were done, and 
measure the total volume of the filtrate. 
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3. Add 2/3 volume 100% ethanol and mix thoroughly: Add 2/3 volume room 
temperature 100% ethanol to filtrate (i.e.flow-through). For example, if 400 μL of filtrate 
is recovered, add 
266 μL 100% ethanol. Mix thoroughly. 
4. Pass the mixture through a second Filter Cartridge, and discard the flow-through: 
a. For each sample, place a F ilter Cartridge into one of the Collection Tubes 
supplied. 
b. Pipet the filtrate/ethanol mixture (from the previous step) onto a second Filter 
Cartridge. Up to 700 μL can be applied to a Filter Cartridge at a time. For sample 
volumes greater than 700 μL, apply the mixture in successive applications to the 
same filter. 
c. Centrifuge for ~15 sec to pass the mixture through the filter. Centrifuge at RCF 
10,000 x g (typically 10,000 rpm). Spinning harder than this may damage the 
filters. Alternatively, vacuum may be used to pass samples through the filter. 
d. Discard the flow-through, and repeat until all of the filtrate/ethanol mixture is 
through the filter. Reuse the Collection Tube for the washing steps. 
5. Wash the filter with 700 μL miRNA Wash Solution 1: 
Apply 700 μL miRNA Wash Solution 1 (working solution mixed with ethanol) to the Filter 
Cartridge and centrifuge for ~5–10 sec or use vacuum to pass the solution through the 
filter. Discard the flow-through from the Collection Tube, and replace the Filter Cartridge 
into thesame Collection Tube. 
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6. Wash the filter twice with500 μL Wash Solution 2/3: 
a. Apply 500 μL Wash Solution 2/3 (working solution mixed with ethanol) and 
draw it through the Filter Cartridge as in the previous step. 
b. Repeat with a second 500 μL aliquot of Wash Solution 2/3. 
c. After discarding the flow-through from the last wash, replace the Filter Cartridge 
in the same Collection Tube and spin the assembly for 1 min to remove residual 
fluid from the filter. 
7. Elute RNA with 100 μL 95°C Elution Solution or Nuclease-free Water: Transfer the 
Filter Cartridge into a fresh Collection Tube (provided with the kit). Apply 100 μL of pre-
heated (95°C) Elution Solution or nuclease-free water to the center of the filter, and close 
the cap. Spin for ~20–30 sec at maximum speed to recover the RNA. Collect the eluate 
(which contains the RNA) and store it at –20°C or colder 
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Appendix VI TaqMan® Small RNA Assays 
http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocuments/cms_0421
67.pdf 
Prepare the RT reaction 
1. Thaw the 5✕ RT primer and RNA template on ice. Before use, vortex the RT primer 
tubes to mix, then centrifuge briefly. 
4. preparing single-stranded RNA, prepare the total RNA template: 
a. For each 15-μL RT reaction, combine RT master mix with total RNA in the ratio of: 7 
μL RT master mix : 5 μL total RNA (1 to 10 ng per reaction) 
b. Mix gently. Centrifuge to bring the solution to the bottom of the tube. 
c. Before opening the RT primer tubes, thaw the tubes on ice and mix by vortexing, then 
centrifuge them. d. For each 15-μL RT reaction, add 12.0 μL of RT master mix containing 
total 
RNA  into a 0.2-mL polypropylene reaction tube (the RT reaction tube) or into a well of a 
96-well reaction plate. 
e. Add 3 μL of 5✕ RT primer from each assay set into the corresponding RT reaction tube 
or plate well. 
5. Seal the tube or reaction plate and mix thoroughly by inverting the solution. Centrifuge 
to bring the solution to the bottom of the tube or well. 
6. Incubate the tube on ice for 5 minutes and keep it on ice until you are ready to load the 
thermal cycler. 
1. Use the following parameter values to program the thermal cycler: 
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Step Time Temperature 
Hold 30 minutes 16 °C 
Hold 30 minutes 42 °C 
Hold 5 minutes 85 °C 
Hold ∞ 4 
 
2. Set the reaction volume to 15.0 μL. 
3. Load the reaction tube or plate into the thermal cycler. 
4. Start the RT run. 
Perform the qPCR amplification 
Thaw and mix the reagents 
1. Thaw on ice, resuspend completely by gently vortexing, then centrifuge briefly: 
• TaqMan® Assay (20✕) 
• Complementary DNA (cDNA) samples 
Calculate the number of reactions Calculate the number of reactions that you need for each 
assay.  
• A small RNA assay for each cDNA sample 
• Endogenous control assay(s) 
• No template controls (NTCs) for each assay on the plate to evaluate background signal. 
The recommended reaction volume is 20 μL. Prepare the plate so that each qPCR 
reaction contains the components as listed below. 
To prepare the qPCR reaction mix: 
1. Obtain a sterile 1.5-mL microcentrifuge tube for each sample (to be run in 
triplicate). 
3. Pipet the following components into each tube: 
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Compone
nt 
Volume per 20-µL Reaction 
Single 
reaction 
Three 
replicates§ 
TaqMan® Small RNA Assay (20✕) 1.00 µL 3.60 µL 
Product from RT reaction* 1.33 µL 4.80 µL 
TaqMan® Universal PCR Master Mix II (2✕), no 
‡ 
10.00 µL 36.00 µL 
Nuclease-free water 7.67 µL 27.61 µL 
Total volume 20.00 µL 72.01 µL 
3. Cap the tube and invert several times to mix. 
4. Centrifuge the tube briefly. 
Prepare the PCR reaction plate 
1. Transfer 20 μL of the complete qPCR reaction mix (including assay and 
RT product) into each of three wells on a 48-, 96-, or 384-well plate. 
2. Seal the plate with the appropriate cover. 
3. Centrifuge the plate briefly. 
4. Load the plate into the instrument. 
 
Set up the experiment or plate document and run the plate 
1.  In the real-time PCR system software, create an experiment or plate document on 
your real-time PCR system using the following parameters: 
• Run Mode: Standard 
• Sample Volume: 20 μL 
• Thermal Cycling Conditions: 
 
Step Optional AmpErase
® 
UNG activity* 
Enzyme 
Activation 
 
PCR 
 
HOLD 
 
HOLD 
CYCLE (40 cycles) 
Denature Anneal/extend 
Temperature 50 °C 95 °C 95 °C 60 °C 
Time 2 minutes 10 minutes 15 seconds 60 seconds 
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2. . If the reaction plate is not already loaded, load the plate into the instrument. 
3.  Start the run. 
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